Publikationen 2018

67. L'Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D'Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT. Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. Leukemia. 2018 Jul 9. [Epub ahead of print]

66. Leblond V, Aktan M, Ferra Coll CM, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot JL, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study. Haematologica. 2018 Jul 5. [Epub ahead of print]

65. Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 Jun 12. [Epub ahead of print]

64. Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. Br J Haematol. 2018 Jun 8. [Epub ahead of print] No abstract available.

63. Fuerst D, Frank S, Mueller C, Beelen DW, Schetelig J, Niederwieser D, Finke J, Bunjes D, Kröger N, Neuchel C, Tsamadou C, Schrezenmeier H, Beyersmann J, Mytilineos J. Competing risks outcomes in hematopoietic stem cell transplantation from the perspective of time-dependent effects. Haematologica. 2018 Jun 7. [Epub ahead of print]

62. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM, Lichter P, Weber U, Eils R, Korshunov A, Witt O, Pfister S, Reifenberger G, Felsberg J, von Kalle C, Schmidt M, Bartholomä C, Taylor M, Pfister S, Jones D, Lichter P, Jäger N, Buchhalter I, Korbel J, Stütz A, Rausch T, Radlwimmer B, Yaspo ML, Lehrach H, Warnatz HJ, Landgraf P, Borkhardt A, Brors B, Zapatka M, Eils R, Eils R, Eils J, Lawerenz C, Siebert R, Wagner S, Haake A, Richter J, Richter G, Eils R, Lawerenz C, Eils J, Kerssemakers J, Jaeger-Schmidt C, Scholz I, Bergmann AK, Borst C, Burkhardt B, Claviez A, Dreyling M, Eberth S, Einsele H, Frickhofen N, Haas S, Hansmann ML, Karsch D, Kneba M, Lisfeld J, Mantovani-Löffler L, Rohde M, Ott G, Stadler C, Staib P, Stilgenbauer S, Trümper L, Zenz T, Hansmann ML, Kube D, Küppers R, Weniger M, Hummel M, Klapper W, Kostezka U, Lenze D, Möller P, Rosenwald A, Ott G, Szczepanowski M, Ammerpohl O, Aukema SM, Binder V, Borkhardt A, Haake A, Hoell JI, Leich E, Lichter P, López C, Nagel I, Pischimariov J, Radlwimmer B, Richter J, Rosenstiel P, Rosenwald A, Schilhabel M, Schreiber S, Vater I, Wagener R, Siebert R, Bernhart SH, Binder H, Brors B, Doose G, Eils R, Hoffmann S, Hopp L, Hübschmann D, Kleinheinz K, Kretzmer H, Kreuz M, Korbel J, Langenberger D, Loeffler M, Rosolowski M, Schlesner M, Stadler PF, Sungalee S; ICGC PedBrain-Seq Project; ICGC MMML-Seq Project; International Cancer Genome Consortium PedBrain Project; Coordination (WP1); Banking (WP2); Reference Pathology & Quality Control (WP3); Isolation of Analytes (WP4); Genomic Sequencing (WP5); Paired-End Mapping (WP6); Methylome Sequencing (WP7); Transcriptome Analysis (WP8); Profiling of small non-coding RNAnome (WP9); Bioinformatics (WP10); Bioinformatics (WP11); International Cancer Genome Consortium MMML-Seq Project, Coordination (C1); Data Center (C2); Clinical Centers (WP1); Normal Cells (WPN); Pathology & Analyte Preparation (WP2-3); Sequencing & genomics (WP4-7); Bioinformatics (WP8-9). Author Correction: The landscape of genomic alterations across childhood cancers. Nature. 2018 Jun 6. [Epub ahead of print]

61. Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, Heerema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018 Jun 5. [Epub ahead of print]

60. Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Future Oncol. 2018 Jun 5. [Epub ahead of print]

59. Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosiñol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, Zhu Y, Skacel T, Moreau P, Richardson PG. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018 May 4. [Epub ahead of print]

58. Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 May 1. [Epub ahead of print]

57. Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 May 30. [Epub ahead of print]

56. Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik M, Huang J, Skorski T. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018 May 21. [Epub ahead of print]

55. Stolzenburg A, Lückerath K, Samnick S, Speer M, Kneer K, Schmid JS, Grigoleit GU, Hofmann S, Beer AJ, Bunjes D, Knop S, Buck AK, Einsele H, Lapa C. Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol Imaging. 2018 Apr 2. [Epub ahead of print]

54. Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, Gresko E, Lundberg L, Moore T, Morris T, Robson S, Bosch F. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2018 Apr 27. [Epub ahead of print]

53. Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia. 2018 Apr 17.[Epub ahead of print]

52. Grasedieck S, Mulaw M, Sperb N, Wessinger K, Rouhi A, Bommer M, Bromberg JEC, Otto M, Tumani H, von Arnim CAF, Mertens D, Kuchenbauer F. Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. Neuropathol Appl Neurobiol. 2018 Apr 21. [Epub ahead of print]

51. Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group. Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. Br J Haematol. 2018 Mar 12. [Epub ahead of print] No abstract available.

50. Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner A, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O. Impact of age on genetics and treatment efficacy in follicular lymphoma. Haematologica. 2018 Mar 15. [Epub ahead of print] No abstract available.

49. L Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT. MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. Leukemia. 2018 Feb 22. [Epub ahead of print].

48. Zajac M, Zaleska J, Dolnik A, Bullinger L, Giannopoulos K. Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML. Br J Haematol. 2017 Dec 19. [Epub ahead of print] No abstract available.

47. Heinemann M, Ranft A, Langer T, Jürgens H, Kreyer J, Vieth V, Schäfers M, Weckesser M, Simon T, Hassenpflug W, Corbacioglu S, Bielack S, Mayer-Steinacker R, Kühne T, van den Berg H, Gelderblom H, Bauer S, Stegger L, Dirksen U. Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage? Pediatr Blood Cancer. 2018 Jul;65(7):e27011. Epub 2018 Feb 26.

46. Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leuk Lymphoma. 2018 Jul;59(7):1614-1623. Epub 2017 Oct 24.

45. Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018 Jul;5(7):e299-e309.

44. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018 Jun 21;131(25):2745-2760. Epub 2018 Mar 14.

43. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. Epub 2018 Jun 1.

42. Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Dtsch Arztebl Int. 2018 May 11;115(19):327-334. [PubMed - in process]

41. Bohl SR, Bullinger L, Rücker FG. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018 May;11(5):361-371. Epub 2018 Mar 27.

40. Sestili S, Labopin M, Ruggeri A, Velardi A, Ciceri F, Maertens J, Kanz L, Aversa F, Lewalle P, Bunjes D, Mohty M, Nagler A. T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia:A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). Cancer. 2018 May 15;124(10):2142-2150. Epub 2018 Feb 22.

39. Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia. 2018 May;32(5):1222-1228. Epub 2018 Feb 26.

38. Schuster AJ, Kager L, Reichardt P, Baumhoer D, Csóka M, Hecker-Nolting S, Lang S, Lorenzen S, Mayer-Steinacker R, von Kalle T, Kevric M, Werner M, Windhager R, Wirth T, Bielack SS. High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients. Sarcoma. 2018 May 2;2018:1632978. eCollection 2018.

37. Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018 May 1;29(5):1266-1272.

36. Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.  Leukemia. 2018 May;32(5):1070-1080. Epub 2018 Feb 2.

35. Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH. The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function. Leukemia. 2018 May;32(5):1211-1221. Epub 2018 Jan 30.

34. Dürr C, Hanna BS, Schulz A, Lucas F, Zucknick M, Benner A, Clear A, Ohl S, Öztürk S, Zenz T, Stilgenbauer S, Li-Weber M, Krammer PH, Gribben JG, Lichter P, Seiffert M. TNF receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica. 2018 Apr;103(4):688-697. Epub 2018 Jan 11.

33. Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, Obulkasim A, Fiedler J, Schwarzer A, Rouhi A, Heuser M, Wingert S, Bothur S, Döhner K, Mätzig T, Ng M, Reinhardt D, Döhner H, Zwaan CM, van den Heuvel Eibrink M, Heckl D, Fornerod M, Thum T, Humphries RK, Rieger MA, Kuchenbauer F, Klusmann JH. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. J Clin Oncol. 2018 Apr 1;36(10):1007-1016. Epub 2018 Feb 12.

32. Frech M, Teichler S, Feld C, Bouchard C, Berberich H, Sorg K, Mernberger M, Bullinger L, Bauer UM, Neubauer A. MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia. Oncotarget. 2018 Apr 27;9(32):22423-22435. eCollection 2018 Apr 27.

31. Schmidberger J, Kratzer W, Stark K, Grüner B; Echinococcosis Working Group. Alveolar echinococcosis in Germany, 1992-2016. An update based on the newly established national AE database. Infection. 2018 Apr;46(2):197-206. Epub 2017 Oct 31.

30. Viardot A, Bargou R. Bispecific antibodies in haematological malignancies. Cancer Treat Rev. 2018 Apr 4;65:87-95. [Epub ahead of print] Review.

29. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Apr 10;24(4):526.

28. Buske C. In Reply. Dtsch Arztebl Int. 2018 Mar 16;115(11):190. No abstract available.

27. Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obländer J, Pressler J, Böhm V, Brüggemann M, Wunderle L, Hüttmann A, Wäsch R, Beck J, Stelljes M, Viardot A, Lang F, Hoelzer D, Hofmann WK, Serve H, Weiss C, Goekbuget N, Ottmann OG, Nowak D. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood. 2018 Mar 29;131(13):1464-1475. Epub 2018 Jan 18.   

26. Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trnený M, Wedding U, Fields P; ESMO Lymphoma Consensus Conference Panel Members. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.  Ann Oncol. 2018 Mar 1;29(3):544-562.

25. Kuchenbauer F, Buske C. Revisiting thrombocytopenia in acute promyelocytic leukemia. Leukemia. 2018 Mar 23. [Epub ahead of print] No abstract available.

24. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018 Mar 22;131(12):1275-1291. Epub 2018 Jan 12.

23. Cramer P, Tresckow JV, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst B, Hallek M. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar;14(6):499-513. Epub 2018 Feb 21.

22. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Mar;24(3):282-291. Epub 2018 Feb 12.

21. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H; ICGC PedBrain-Seq Project; ICGC MMML-Seq Project, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM. Stilgenbauer S as Collaborator. The landscape of genomic alterations across childhood cancers. Nature. 2018 Mar 15;555(7696):321-327. Epub 2018 Feb 28.

20. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, Moreno C, Stilgenbauer S.Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018 Mar;180(5):666-679.  Epub 2018 Jan 9.   

19. Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018 Feb 15;9(1):697.

18. Schneider E, Staffas A, Röhner L, Malmberg ED, Ashouri A, Krowiorz K, Pochert N, Miller C, Wei SY, Arabanian L, Buske C, Döhner H, Bullinger L, Fogelstrand L, Heuser M, Döhner K, Xiang P, Ruschmann J, Petriv OI, Heravi-Moussavi A, Hansen CL, Hirst M, Humphries RK, Rouhi A, Palmqvist L, Kuchenbauer F. MicroRNA-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia. Haematologica. 2018 Feb;103(2):246-255. Epub 2017 Dec 7.

17. Bernhardt P, Kratzer W, Schmidberger J, Graeter T, Gruener B; EMIL Study Group. Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis. BMC Res Notes. 2018 Feb 6;11(1):101.

16. Lisson CS, Lisson CG, Flosdorf K, Mayer-Steinacker R, Schultheiss M, von Baer A, Barth TFE, Beer AJ, Baumhauer M, Meier R, Beer M, Schmidt SA. Diagnostic value of MRI-based 3D texture analysis for tissue characterisation and discrimination of low-grade chondrosarcoma from enchondroma: a pilot study. Eur Radiol. 2018 Feb;28(2):468-477.   

15. Osin R, Pankrath AL, Niederwieser D, Döhner H, Hönig K, Vogelhuber M, Mehnert A, Weißflog G, Ernst J. [Dyadic Coping of Patients with Haemato-Oncological Diseases and their Partners: Discrepancy Indexes and Association with Social Support and Psychological Distress]. Psychother Psychosom Med Psychol. 2018 Feb;68(2):55-65.

14. Solomon N, Zeyhle E, Subramanian K, Fields PJ, Romig T, Kern P, Carter JY, Wachira J, Mengiste A, Macpherson CNL. Cystic echinococcosis in Turkana, Kenya: 30 years of imaging in an endemic region. Acta Trop. Acta Trop. 2018 Feb;178:182-189.   

13. Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A. Lamin B1 regulates somatic mutations and progression of B-cell malignancies.   Leukemia. 2018 Feb;32(2):364-375. 

12. Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P. Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol. 2018 Feb 19;20(3):400-410.

11. Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; & the ESMO Lymphoma Consensus Conference Panel Members. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol. 2018 Feb 1;29(2):525.   

10. Mandal T, Beck M, Kirsten N, Lindén M, Buske C. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles. Sci Rep. 2018 Jan 17;8(1):989.  

9. Jeck J, Kassubek R, Coburger J, Edenhofer S, Schönsteiner SS, Ludolph AC, Schmitz B, Engelke J, Mayer-Steinacker R, Lewerenz J, Bullinger L. Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. Ther Adv Neurol Disord. 2018 Jan 21;11:1756285617753597. eCollection 2018.

8. Buske C, Dreyling M. [Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma]. Dtsch Med Wochenschr. 2018 Jan;143(1):46-51. Epub 2018 Jan 9. German. No abstract available.   

7. Rücker FG, Dolnik A, Blätte TJ, Teleanu V, Ernst A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K, Bullinger L.Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype.  Haematologica. 2018 Jan;103(1):e17-e20. No abstract available.   

6. Wais V, Kündgen L, Bohl SR, von Harsdorf S, Schlenk RF, Döhner K, Teleanu V, Bullinger L, Nguyen TM, Drognitz K, Moulin JC, Binnenhei M, Bentz M, Döhner H, Bunjes D, Kuchenbauer F, Ringhoffer M. Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome. Bone Marrow Transplant. 2018 Jan;53(1):94-96.   

5. Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak GA, Othman TB, Halkes CJM, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano AM, Ehninger G, Porcher R, Dufour C; EBMT SAA WP. Bunjes D as Collaborator Transplant results in adults with Fanconi anaemia. Br J Haematol. 2018 Jan;180(1):100-109.   

4. Pankrath AL, Weißflog G, Mehnert A, Niederwieser D, Döhner H, Hönig K, Gündel H, Vogelhuber M, Friedrich M, Ernst J. The relation between dyadic coping and relationship satisfaction in couples dealing with haematological cancer. Eur J Cancer Care (Engl). 2018 Jan;27(1).Epub 2016 Oct 24.

3. Nickel K, Renovanz M, König J, Stöckelmaier L, Hickmann AK, Nadji-Ohl M, Engelke J, Weimann E, Freudenstein D, Ganslandt O, Bullinger L, Wirtz CR, Coburger J. The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study. Neurosurg Rev. 2018 Jan;41(1):207-219.  

2. Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, Zucknick M, Rouhi A, Weigel A, Claus R, Weichenhan D, Eichhorst B, Fischer K, Hallek M, Kuchenbauer F, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D.NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 Jan 15;142(2):322-333.   

1. Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K.DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018 Jan;32(1):30-37.   

Publikationen 2017

129.  Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.  Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.  BMC Cancer. 2017 Dec 14;17(1):852.

128.  Hirsch S, Blätte TJ, Grasedieck S, Cocciardi S, Rouhi A, Jongen-Lavrencic M, Paschka P, Krönke J, Gaidzik VI, Döhner H, Schlenk RF, Kuchenbauer F, Döhner K, Dolnik A, Bullinger L.  Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.  Haematologica. 2017 Dec;102(12):2039-2047.

127.  Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.  Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.  Blood. 2017 Dec 14;130(24):2610-2618.

126.  Greiner J, Hofmann S, Schmitt M, Götz M, Wiesneth M, Schrezenmeier H, Bunjes D, Döhner H, Bullinger L.  Acute myeloid leukemia with mutated nucleophosmin 1 - an immunogenic AML subtype and potential candidate for immune checkpoint inhibition.  Haematologica. 2017 Dec;102(12):e499-e501

125.  Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner SS, Rouhi A, Schwarzwälder P,Döhner H, Bunjes D, Bommer M.  Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation - a Comparison of Eculizumab Therapy and Conventional Therapy.  Biol Blood Marrow Transplant. 2017 Dec;23(12):2172-2177.

124.  Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H,  Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S.  Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.  Leukemia. 2017 Dec;31(12):2833-2837.

123.  Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A  PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.  Lancet. 2017 Dec 23;390(10114):2790-2802.

122.  Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.  Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.  Leuk Res. 2017 Dec;63:34-40. Epub 2017 Oct 14.

121.  Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).  Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)  Ann Hematol. 2017 Dec;96(12):1993-2003. Epub 2017 Oct 31.

120.  Krönke J, Knop S, Langer C.  Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.  Oncotarget. 2017 Nov 21;8(63):106163-106164.

119.  Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S.  Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.  J Clin Oncol. 2016 Nov 1;34(31):3758-3765.

118.  Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR.  Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia.  Blood. 2017 Nov 30;130(22):2443-2444.

117.  Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.  BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.  Nature. 2017 Nov 16;551(7680):384-388. Epub 2017 Nov 8.

116.  Stone RM, Larson RA, Döhner H.  Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.  N Engl J Med. 2017 Nov 9;377(19):1903.

115.  Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A.  Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.  J Hematol Oncol. 2016 Nov 8;9(1):118.

114.  Xiang P, Wei W, Hofs N, Clemans-Gibbon J, Maetzig T, Lai CK, Dhillon I, May C, Ruschmann J, Schneider E, Rosten P, Hu K, Kuchenbauer F, Hoodless PA, Humphries RK.  A knock-in mouse strain facilitates dynamic tracking and enrichment of MEIS1.  Blood Adv. 2017 Nov 7;1(24):2225-2235.

113.  Grunenberg A, Buske C.  Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.  Dtsch Arztebl Int. 2017 Nov 3;114(44):745-751.

112.  Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).  Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.  Lancet Haematol. 2017 Nov;4(11):e510-e523. Epub 2017 Oct 17.

111.  Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S.  Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.  Br J Haematol. 2017 Nov;179(4):586-597.

110.  Tsamadou C, Fürst D, Vucinic V, Bunjes D, Neuchel C, Mytilineos D, Gramatzki M, Arnold R, Wagner EM, Einsele H, Müller C, Schrezenmeier H, Mytilineos J.  HLA-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients.  Haematologica. 2017 Nov;102(11):1947-1955.

109.  Feiner-Gracia N, Beck M, Pujals S, Tosi S, Mandal T, Buske C, Linden M, Albertazzi L  Super-Resolution Microscopy Unveils Dynamic Heterogeneities in Nanoparticle Protein Corona.  Small. 2017 Nov;13(41).

108.  Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.  Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10–year survival results of the randomized CML study IV and impact of non-CML determinants.  Leukemia. 2017 Nov;31(11):2398-2406.

107.  Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.  The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.  Exp Hematol. 2017 Nov;55:76-85.e3.

106.  Thiel VN, Giaimo BD, Schwarz P, Soller K, Vas V, Bartkuhn M, Blätte TJ, Döhner K, Bullinger L, Borggrefe T, Geiger H, Oswald F.  Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.  Leukemia. 2017 Nov;31(11):2491-2502.

105.  Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS.  Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in <i>FLT3</i>-ITD AML with concurrent epigenetic mutations.  Oncotarget. 2017 Oct 16;8(65):108738-108759. eCollection 2017 Dec 12.

104.  Kobitzsch B, Gökbuget N, Schwartz S, Reinhardt R, Brüggemann M, Viardot A, Wäsch R, Starck M, Thiel E, Hoelzer D, Burmeister T.  Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.  Haematologica. 2017 Oct;102(10):1739-1747.

103.  Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G.  Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.  Leukemia. 2017 Oct;31(10):2251-2253.

102.  Scheffold A, Jebaraj BM, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S.  Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.  Br J Haematol. 2017 Oct;179(2):342-346. No abstract available.

101.  Hess M, Lenz S, Blätte TJ, Bullinger L, Binder H.  Partitioned learning of deep Boltzmann machines for SNP data.  Bioinformatics. 2017 Oct 15;33(20):3173-3180.

100.  Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, Tausch E, Taylor-Weiner A, Cibulskis C, Bahl S, Fernandes SM, Hoang K, Rheinbay E, Kim HT, Bahlo J, Robrecht S, Fischer K, Hallek M, Gabriel S, Lander ES, Stilgenbauer S, Wu CJ, Kiezun A, Getz G, Brown JR.  Rare germline variants in ATM are associated with chronic lymphocytic leukemia.  Leukemia. 2017 Oct;31(10):2244-2247.

99.  Liu X, Pichulik T, Wolz O, Dang TM, Stutz A, Dillen C, Delmiro Garcia M, Kraus H, Dickhöfer S, Daiber E, Münzenmayer L, Wahl S, Rieber N, Kümmerle-Deschner J, Yazdi A, Franz-Wachtel M, Macek B, Radsak M, Vogel S, Schulte B, Walz JS, Hartl D, Latz E, Stilgenbauer S, Grimbacher B, Miller L, Brunner C, Wolz C, Weber AN.  Human NLRP3 inflammasome activity is regulated by and potentially targetable via BTK.  J Allergy Clin Immunol. 2017 Oct;140(4):1054-1067.e10. Epub 2017 Feb 16.

98.  Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D,Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU.  Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT.  Leukemia. 2017 Oct;31(10):2161-2171.

97.  Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M.  Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.  Lancet Haematol. 2017 Oct; 4(10):e475-e486. Epub 2017 Sep 12.

96.  Zenz T, Kreuz M, Fuge M, Klapper W, Horn H, Staiger AM, Winter D, Helfrich H, Huellein J, Hansmann ML, Stein H, Feller A, Möller P, Schmitz N, Trümper L, Loeffler M, Siebert R, Rosenwald A, Ott G, Pfreundschuh M, Stilgenbauer S; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).  TP53 mutation and survival in aggressive B cell lymphoma.  Int J Cancer. 2017 Oct 1;141(7):1381-1388.

95.  Herzig JK,Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI.  Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.  Oncotarget. 2017 Sep 21;8(56):95038-95053.

94.  Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P  Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.  Blood. 2017 Sep 21;130(12):1477-1480. No abstract available.

93.  Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.  Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.  Ann Hematol. 2017 Sep;96(9):1463-1470.

92.  Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek D, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.  Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.  Clin Cancer Res. 2017 Sep 1;23(17):5292-5301.

91.  Liu Y, Steinestel K, Rouhi A, Armacki M, Diepold K, Chiosis G, Simmet T, Seufferlein T, Azoitei N.  STK33 participates to HSP90-supported angiogenic program in hypoxic tumors by regulating HIF-1α/VEGF signaling pathway.  Oncotarget. 2017 Aug 24;8(44):77474-77488.

90.  Schwarzer A, Emmrich S, Schmidt F, Beck D, Ng M, Reimer C, Adams FF, Grasedieck S, Witte D, Käbler S, Wong JWH, Shah A, Huang Y, Jammal R, Maroz A, Jongen-Lavrencic M, Schambach A, Kuchenbauer F, Pimanda JE, Reinhardt D, Heckl D, Klusmann JH.  The non-coding RNA landscape of human hematopoiesis and leukemia.  Nat Commun. 2017 Aug 9;8(1):218.

89.  Zajac M, Dolnik A, Stasiak G, Zaleska J, Kielbus M, Czapinski J, Schunn M, Correa SC, Glodkowska-Mrowka E, Sundaram RC, Jankowska-Lecka O, Schlenk RF, Döhner H, Döhner K, Stepulak A, Bullinger L, Giannopoulos K.  Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.  Oncotarget. 2017 Aug 3;8(56):95163-95175.

88.  Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.  N Engl J Med. 2017 Aug 3;377(5):454-464

87.  Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B.  Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.  Lancet Haematol. 2017 Aug;4(8):e362-e373.

86.  Lingscheid T, Kurth F, Clerinx J, Marocco S, Trevino B, Schunk M, Muñoz J, Gjørup IE, Jelinek T, Develoux M, Fry G, Jänisch T, Schmid ML, Bouchaud O, Puente S, Zammarchi L, Mørch K, Björkman A, Siikamäki H, Neumayr A, Nielsen H, Hellgren  U, Paul M, Calleri G, Kosina P, Myrvang B, Ramos JM, Just-Nübling G, Beltrame A,  Saraiva da Cunha J, Kern P, Rochat L, Stich A, Pongratz P, Grobusch MP, Suttorp N, Witzenrath M, Hatz C, Zoller T, TropNet Schistosomiasis Investigator Group.  Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data.  Am J Trop Med Hyg. 2017 Aug;97(2):567-574.

85.  Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Härter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gökbuget N; AmBiGuard Study Group.  Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.  J Antimicrob Chemother. 2017 Aug 1;72(8):2359-2367.

84.  Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC.  Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma.  Leukemia. 2017 Aug;31(8):1816-1819.

83.  Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Dohner K, Marquardt JU, Heidel F, Edlich F.  Mitochondrial BAX determines the predisposition to apoptosis in human AML.  Clin Cancer Res. 2017 Aug 15;23(16):4805-4816.

82.  Roberts AW, Stilgenbauer S, Seymour JF, Huang DC.  Venetoclax in patients with previously treated chronic lymphocytic leukemia.  Clin Cancer Res. 2017 Aug 15;23(16):4527-4533.

81.  Schuh AC, Döhner H, Pleyer L, Seymour JF, Fenaux P, Dombret H.  Azacitidine in adult patients with acute myeloid leukemia.  Crit Rev Oncol Hematol. 2017 Aug;116:159-177. Review.

80.  Lauseker M, Hasford J, Saussele S, Kremers S, Kraemer D, Lindemann W, Hehlmann R, Pfirrmann M; German CML Study Group.  Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.  Cancer. 2017 Jul 1;123(13):2467-2471.

79.  Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H,Richter J, Buske C; ESMO Guidelines Committee.  Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51.

78.  Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee..  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.  Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. No abstract available.

77.  Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC.  Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.  Nat Commun. 2017 Jul 28;8(1):153.

76.  Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, Schulz A, Warnken U, Seiler J, Benner A, Nessling M, Zenz T, Göbel M, Dürig J, Diederichs S, Paggetti J, Moussay E, Stilgenbauer S, Zapatka M, Lichter P, Seiffert M.  Tumor-derived exosomes modulate PD-L1 expression in monocytes.  Sci Immunol. 2017 Jul 28;2(13).

75.  Thomsen H, Campo C, Weinhold N, Filho MI, Pour L, Gregora E, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Goldschmidt H, Hemminki K, Försti A.  Genome-wide association study on monoclonal gammopathy of unknown significance (MGUS).  Eur J Haematol. 2017 Jul;99(1):70-79

74.  Seymour JF, Döhner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H.  Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.  Leuk Lymphoma. 2017 Jun;58(6):1412-1423.

73.  Beck M, Mandal T, Buske C, Lindén M.  Serum protein adsorption enhances active leukemia stem cell targeting of mesoporous silica nanoparticles.  ACS Appl Mater Interfaces. 2017 Jun 7;9(22):18566-18574.

72.  Stöckelmaier L, Renovanz M, König J, Nickel K, Hickmann AK, Mayer-Steinacker R, Nadji-Ohl M, Ganslandt O, Bullinger L, Wirtz CR, Coburger J.  Therapy for recurrent high-grade gliomas: Results of a prospective multicenter study on health-related quality of life.  World Neurosurg. 2017 Jun;102:383-399.

71.  Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C.  Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.  Leukemia. 2017 Jun;31(6):1463-1466.

70.  Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C.  IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).  Leukemia. 2017 Jun;31(6):1363-1367.

69.  Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.  Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.  Leukemia. 2017 Jun;31(6):1306-1313.

68.  Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichman M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk R, Döhner K, Döhner H, Ganser A, Heuser M.  Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.  Leukemia. 2017 Jun;31(6):1286-1295.

67.  Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JCY, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.  Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.  J Clin Invest. 2017 Jun 1;127(6):2392-2406.

66.  Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.  Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.  J Hematol Oncol. 2017 Jun 24;10(1):130.

65.  Rohde M, Bonn BR, Zimmermann M, Lange J, Möricke A, Klapper W, Oschlies I, Szczepanowski M, Nagel I, Schrappe M, Loeffler M, Siebert R, Reiter A, Burkhardt B; ICGC-MMML-Seq; MMML-MYC-SYS.  Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the NHL-BFM protocols.  Haematologica.  2017 Jun;102(6):1091-1098.

64.  Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC).  Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.  Haematologica. 2017 Jun;102(6):968-971. No abstract available.

63.  Went M, Sud A, Law PJ, Johnson DC, Weinhold N, Försti A, van Duin M, Mitchell JS, Chen B, Kuiper R, Stephens OW, Bertsch U, Campo C, Einsele H, Gregory WM, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Langer C, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson B, Morgan GJ, Houlston RS.  Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.  Blood Cancer J. 2017 Jun 16;7(6):e573.

62.  Edenhofer SA, Stilgenbauer S.  Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.  J Oncol Pract. 2017 Jun;13(6):381-382.

61.  Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D.  Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.  Ann Hematol. 2017 Jun;96(6):887-894.

60.  Schuler PJ, Laban S, Doescher J, Bullinger L, Hoffmann TK.  Novel Treatment Options in Head and Neck Cancer.  Oncol Res Treat. 2017 May 17;40(6).

59.  Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.  Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.  Blood Cancer J. 2017 May 26;7(5):e564.

58.  Ricken FJ, Nell J, Grüner B, Schmidberger J, Kaltenbach T, Kratzer W, Hillenbrand A, Henne-Bruns D, Deplazes P, Moller P, Kern P, Barth TFE.  Albendazole increases the inflammatory response and the amount of Em2-positive small particles of Echinococcus multilocularis (spems) in human hepatic alveolar echinococcosis lesions.  PLoS Negl Trop Dis. 2017 May 25;11(5):e0005636. eCollection 2017 May.

57.  Jäger D, Barth TFE, Brüderlein S, Scheuerle A, Rinner B, von Witzleben A, Lechel A, Meyer P, Mayer-Steinacker R, Baer AV, Schultheiss M, Wirtz CR, Möller P, Mellert K.  HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.  Sci Rep. 2017 May 17;7(1):2032.

56.  Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJ, Boettcher S, Ritgen M, Goede V, Mobasher M, Hallek M.  Venetoclax and obinutuzumab in chronic lymphocytic leukemia.  Blood.  2017 May 11;129(19):2702-2705.

55.  Lal R, Lind K, Heitzer E, Ulz P, Aubell K, Kashofer K, Middeke JM, Thiede C, Schulz E, Rosenberger A, Hofer S, Feilhauer B, Rinner B, Svendova V, Schimek MG, Rücker FG, Hoefler G, Döhner K, Zebisch A, Wölfler A, Sill H.  Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.  Blood. 2017 May 4;129(18):2587-2591.

54.  Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; and for the German-Austrian AMLSG.  Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.  Leukemia. 2017 May;31(5):1217-1220.

53.  Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M.  Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.  Leukemia. 2017 May;31(5):1177-1186.

52.  Buske C, Ogura M, Kwon HC, Yoon SW.  An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.  Future Oncol. 2017 May;13(15s):5-16.

51.  Weißflog G, Hönig K, Gündel H, Lang D, Niederwieser D, Döhner H, Vogelhuber M, Mehnert A, Ernst J.  Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners.  Support Care Cancer. 2017 May;25(5):1445-1454.

50.  Itkin T, Kumari A, Schneider E, Gur-Cohen S, Ludwig C, Brooks R, Kollet O, Golan K, Khatib-Massalha E, Russo CM, Chisholm JD, Rouhi A, Geiger H, Hornstein E, Kerr WG, Kuchenbauer F, Lapidot T.  MicroRNA-155 promotes G-CSF-induced mobilization of murine hematopoietic stem and progenitor cells via propagation of CXCL12 signaling.  Leukemia. 2017 May;31(5):1247-1250.

49.  Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T.  Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.  Cancer Cell. 2017 Apr 10;31(4):549-562.e11.

48.  Halvarsson BM, Wihlborg AK, Ali M, Lemonakis K, Johnsson E, Niroula A, Cibulskis C, Weinhold N, Försti A, Alici E, Langer C, Pfreundschuh M, Goldschmidt H, Mellqvist UH, Turesson I, Waage A, Hemminki K, Golub T, Nahi H, Gullberg U, Hansson M, Nilsson B.  Direct evidence for a polygenic etiology in familial multiple myeloma.  Blood Adv. 2017 Apr 7;1(10):619-623. eCollection 2017 Apr 11.

47.  Budke CM, Casulli A, Kern P, Vuitton DA.  Cystic and alveolar echinococcosis: Successes and continuing challenges.  PLoS Negl Trop Dis. 2017 Apr 20;11(4):e0005477.

46.  Brown AL, Churpek JE, Malcovati L, Döhner H, Godley LA.  Recognition of familial myeloid neoplasia in adults.  Semin Hematol. 2017 Apr;54(2):60-68. Epub 2017 Apr 18. Review.

45.  Schmitt M, Schmitt A, Wiesneth M, Hückelhoven A, Wu Z, Kuball J, Wang L, Schauwecker P, Hofmann S, Götz M, Michels B, Maccari B, Wuchter P, Eckstein V, Mertens T, Schnitzler P, Döhner H, Ho AD, Bunjes DW, Dreger P, Schrezenmeier H, Greiner J.  Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.  Theranostics. 2017 Apr 10;7(6):1705-1718. eCollection 2017.

44.  Kassubek R, Bullinger L, Kassubek J, Dreyhaupt J, Ludolph AC, Althaus K, Lewerenz J.  Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.  J Neurol. 2017 Apr;264(4):781-791.

43.  Schlenk RF*, Stegelmann F*, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K, *equal contribution.  Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.  Leukemia.2017 Apr;31(4):889-895.

42.  Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.  Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG).  Leukemia. 2017 Apr;31(4):1012-1015.

41.  Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.  Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.  Lancet Oncol. 2017 Apr;18(4):454-463. Epub 2017 Feb 22.

40.  Addy F, Wassermann M, Banda F, Mbaya H, Aschenborn J, Aschenborn O, Koskei P, Umhang G, DE LA Rue M, Elmahdi IE, Mackenstedt U, Kern P, Romig T.  Genetic polymorphism and population structure of Echinococcus ortleppi.  Parasitology. 2017 Apr;144(4):450-458. Epub 2016 Dec 12.

39.  Hillenbrand A, Gruener B, Kratzer W, Kern P, Graeter T, Barth TF, Buttenschoen K, Henne-Bruns D.  Impact of Safe Distance on Long-Term Outcome After Surgical Therapy of Alveolar Echinococcosis.  World J Surg. 2017 Apr;41(4):1012-1018.

38.  Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK.  Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.  Haematologica. 2017 Apr;102(4):e156-e159. 2016 Dec 15. No abstract available.

37.  Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R.  Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.  Haematologica. 2017 Apr;102(4):e132-e135. No abstract available.

36.  Fürst D, Niederwieser D, Bunjes D, Wagner EM, Gramatzki M, Wulf G, Müller CR, Neuchel C, Tsamadou C, Schrezenmeier H, Mytilineos J.  Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.  Haematologica. 2017 Apr;102(4):796-803.

35.  Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.  Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.  Ann Hematol. 2017 Apr;96(4):559-565.

34.  Ernst J, Hinz A, Niederwieser D, Döhner H, Hönig K, Vogelhuber M, Mehnert A, Weissflog G  Dyadic coping of patients with hematologic malignancies and their partners and its relation to quality of life - a longitudinal study.  Leuk Lymphoma. 2017 Mar;58(3):655-665.

33.  Khadivjam B, Stegen C, Hogue-Racine MA, El Bilali N, Döhner K, Sodeik B, Lippé R.  The ATP-Dependent RNA Helicase DDX3X Modulates Herpes Simplex Virus 1 Gene Expression.  J Virol. 2017 Mar 29;91(8).

32.  Bullinger L, Döhner K, Döhner H.  Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.  J Clin Oncol. 2017 Mar 20;35(9):934-946. Epub 2017 Feb 13.

31.  Mertens D, Stilgenbauer S.  Ibrutinib-resistant CLL: unwanted and unwonted!  Blood. 2017 Mar 16;129(11):1407-1409. No abstract available.

30.  Tasdogan A, Kumar S, Allies G, Bausinger J, Beckel F, Hofemeister H, Mulaw M, Madan V, Scharffetter-Kochanek K, Feuring-Buske M, Doehner K, Speit G, Stewart AF, Fehling HJ.  DNA Damage-Induced HSPC Malfunction Depends on ROS Accumulation Downstream of IFN-1 Signaling and Bid Mobilization.  Cell Stem Cell. 2017 Mar 2;20(3):415. No abstract available.

29.  van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.  Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.  Bone Marrow Transplant. 2017 Mar;52(3):372-380. 2016 Dec 12.

28.  Staffas A, Arabanian LS, Wei SY, Jansson A, Ståhlman S, Johansson P, Fogelstrand L, Cammenga J, Kuchenbauer F, Palmqvist L.  Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.  Oncogene. 2017 Mar;36(11):1516-1524.

27.  Gerstung M,* Papaemmanuil E,* Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H,* Campbell PJ.*  Precision oncology for acute myeloid leukemia using a knowledge bank approach.  Nat Genet. 2017 Mar;49(3):332-340. 2017 Jan 16.  *Equal contribution

26.  Schwameis M, Kündig T, Huber G, von Bidder L, Meinel L, Weisser R, Aberer E, Härter G, Weinke T, Jelinek T, Fätkenheuer G, Wollina U, Burchard GD, Aschoff R, Nischik R, Sattler G, Popp G, Lotte W, Wiechert D, Eder G, Maus O, Staubach-Renz P, Gräfe A, Geigenberger V, Naudts I, Sebastian M, Reider N, Weber R, Heckmann M, Reisinger EC, Klein G, Wantzen J, Jilma B.  Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial.  Lancet Infect Dis. 2017 Mar;17(3):322-329.

25.  Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P.  Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.  Lancet Oncol. 2017 Mar;18(3):297-311.

24.  Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O.  Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells.  Exp Hematol. 2017 Mar;47:54-63.

23.  Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM.  Alemtuzumab consolidation in chronic lymphocytic leukaemia: A phase I/II multicentre trial.  Eur J Haematol. 2017 Mar;98(3):254-262.

22.  Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S.  Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.  Leukemia. 2017 Mar;31(3):734-738.

21.  Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizcaychipi KA, Budke C, Vuitton DA.  The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease.  Adv Parasitol. 2017;96:259-369.

20.  Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Investigators.  Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.  Leuk Lymphoma. 2017 Feb;58(2):348-356.

19.  Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M.  Mutational landscape reflects the biological continuum of plasma cell dyscrasias.  Blood Cancer J. 2017 Feb 24;7(2):e537.

18.  Bohl SR, Dolnik A, Jensen T, Lang KM, Hackanson B, Gaidzik VI, Paschka P, Knudsen S, Döhner K, Döhner H, Claus R, Lübbert M, Bullinger L.  Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.  Leuk Lymphoma. 2017 Feb 13:1-4. No abstract available.

17.  Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia..  Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.  Lancet Oncol. 2017 Feb;18(2):241-250. 2016 Dec 9.

16.  Qu Y, Siggens L, Cordeddu L, Gaidzik VI, Karlsson K, Bullinger L, Döhner K, Ekwall K, Lehmann S, Lennartsson A  Cancer specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.  Blood. 2017 Feb 16;129(7):e13-e25.

15.  Chakrabortty S, Agrawalla BK, Stumper A, Vegi NM, Fischer S, Reichardt C, Kögler M, Dietzek B, Feuring-Buske M, Buske C, Rau S, Weil T.  Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications.  J Am Chem Soc. 2017 Feb 15;139(6):2512-2519.

14.  Schönsteiner S*, Bauder Mißbach H, Benner A, Mack S, Hamel T, Orth M, Landwehrmeyer B, Süßmuth S, Geitner C, Mayer‑Steinacker R, Riester A, Prokein A, Erhardt E, Kunecki J, Eisenschink A, Rawer R, Döhner H, Kirchner R, Schlenk RF  A randomized exploratory phase 2 study in patients with chemotherapy‑related peripheral neuropathy evaluating whole‑body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.  Exp Hematol Oncol. 2017 Feb 7;6:5. eCollection 2017.

13.  Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.  Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.  Int J Mol Sci. 2017 Feb 15;18(2).

12.  Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S.  Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.  Onco Targets Ther. 2017 Feb 7;10:645-656. eCollection 2017.

11.  Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, Rambaldi A, Kanz L, Messina G, Mohty M, Nagler A.  Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.  Bone Marrow Transplant. 2017 Feb;52(2):238-244.

10.  Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.  Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.  J Clin Oncol. 2017 Feb 20;35(6):605-612.

9.  Robak T, Stilgenbauer S, Tedeschi A.  Front-line treatment of CLL in the era of novel agents.  Cancer Treat Rev. 2017 Feb;53:70-78. Review

8.  Dezsényi B, Strausz T, Makrai Z, Csomor J, Danka J, Kern P, Rezza G, Barth TF, Casulli A.  Autochthonous human alveolar echinococcosis in a Hungarian patient.  Infection. 2017 Feb;45(1):107-110.

7.  Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C.  Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.  Oncotarget. 2017 Jan 31;8(5):7678-7690.

6.  Kurth F, Develoux M, Mechain M, Malvy D, Clerinx J, Antinori S, Gjørup IE, Gascon J, Mørch K, Nicastri E, Ramharter M, Bartoloni A, Visser L, Rolling T, Zanger P, Calleri G, Salas-Coronas J, Nielsen H, Just-Nübling G, Neumayr A, Hachfeld A, Schmid ML, Antonini P, Lingscheid T, Kern P, Kapaun A, da Cunha JS, Pongratz P, Soriano-Arandes A, Schunk M, Suttorp N, Hatz C, Zoller T.  Severe malaria in Europe: an 8-year multi-centre observational study.  Malar J. 2017 Jan 31;16(1):57.

5.  Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.  Blood. 2017 Jan 26;129(4):424-447.

4.  Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C.  Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.  Blood. 2017 Jan 19;129(3):319-323.

3.  Neuchel C, Fürst D, Niederwieser D, Bunjes D, Tsamadou C, Wulf G, Pfreundschuh M, Wagner E, Stuhler G, Einsele H, Schrezenmeier H, Mytilineos J.  Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.  PLoS One. 2017 Jan 20;12(1):e0169512.

2.  Buske C.  Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?  Lancet Haematol. 2017 Jan;4(1):e4-e5.

1.  Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.  Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group.  Haematologica. 2017 Jan;102(1):85-93.  1.  Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, Friebe-Hoffmann U, Bullinger L, Möller P, Wiegel T.  Response Evaluation in Head and Neck Oncology: Definition and Prediction.  ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):14-23.

 

Publikationen 2016

 

109. Robak T, Stilgenbauer S, Tedeschi A. Front-line treatment of CLL in the era of novel agents. Cancer Treat Rev. 2016 Dec 30;53:70-78. Review.

108. Gentner E, Vegi NM, Mulaw MA, Mandal T, Bamezai S, Claus R, Tasdogan A, Quintanilla-Martinez L, Grunenberg A, Döhner K, Döhner H, Bullinger L, Haferlach T, Buske C, Rawat VP, Feuring-Buske M. VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice. Oncotarget. 2016 Dec 27;7(52):86889-86901.

107. Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016 Dec 15;540(7633):433-437. 

106. Krowiorz K, Ruschmann J, Lai C, Ngom M, Maetzig T, Martins V, Scheffold A, Schneider E, Pochert N, Miller C, Palmqvist L, Staffas A, Mulaw M, Bohl SR, Buske C, Heuser M, Kraus J, O'Neill K, Hansen CL, Petriv OI, Kestler H, Döhner H, Bullinger L, Döhner K, Humphries RK, Rouhi A, Kuchenbauer F. MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J. 2016 Dec 9;6(12):e508. No abstract available.

105. Schlenk RF. Is there justification for 4 cycles of consolidation therapy in AML? Best Pract Res Clin Haematol. 2016 Dec;29(4):341-344. Review.

104. Fuerst D, Neuchel C, Niederwieser D, Bunjes D, Gramatzki M, Wagner E, Wulf G, Glass B, Pfreundschuh M, Einsele H, Arnold R, Stuhler G, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Wattad M, Hertenstein B, Klein S, Ringhoffer M, Mytilineos D, Tsamadou C, Mueller C, Schrezenmeier H, Mytilineos J. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. Blood. 2016 Dec 29;128(26):3169-3176.

103. Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner K, Döhner H, Bullinger L, Zhang J, Klco JM, Downing JR. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016 Dec;48(12):1551-1556.  

102. Tasdogan A, Kumar S, Allies G, Bausinger J, Beckel F, Hofemeister H, Mulaw M, Madan V, Scharfetter-Kochanek K, Feuring-Buske M, Doehner K, Speit G, Stewart AF, Fehling HJ. DNA Damage-Induced HSPC Malfunction Depends on ROS Accumulation Downstream of IFN-1 Signaling and Bid Mobilization. Cell Stem Cell. 2016 Dec 1;19(6):752-767.

101. Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; ESMO Lymphoma Consensus Conference Panel Members. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol. 2016 Dec;27(12):2149-2160.

100. von Witzleben A, Goerttler LT, Lennerz J, Weissinger S, Kornmann M, Mayer-Steinacker R, von Baer A, Schultheiss M, Möller P, Barth TF. In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients' shorter overall survival. Eur Spine J. 2016 Dec;25(12):4016-4024. Epub 2015 Sep 23.

99. Schneider E, Staffas A, Röhner L, Krowiorz K, Heuser M, Döhner K, Bullinger L, Döhner H, Fogelstrand L, Rouhi A,Kuchenbauer F, Palmqvist L. MicroRNA-155 is upregulated in MLL rearranged AML but its absence does not affect leukemia development. Exp Hematol. 2016 Dec;44(12):1166-1171. Epub 2016 Sep 13.

98. Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro J, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125.

97. Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik V, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. Ann Hematol. 2016 Dec; 95(12):1931:1942.

96. Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.  J Hematol Oncol. 2016 Nov 8;9(1):118.

95. Kratzer W, Gruener B, Kaltenbach TE, Ansari-Bitzenberger S, Kern P, Fuchs M, Mason RA, Barth TF, Haenle MM, Hillenbrand A, Oeztuerk S, Graeter T. Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: Echinococcosis multilocularis Ulm classification-ultrasound. World J Gastroenterol. 2015 Nov 21;21(43):12392-402.

94. Bullinger L. T-lymphoid progenitors - we know what they are, but know not what they may be. EMBO J. 2016 Nov 15;35(22):2383-2385.

93. Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf HH, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H; DSMM (Deutsche Studiengruppe Multiples Myelom). Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016 Nov;101(11):1398-1406.

92. Shivarov V, Dolnik A, Lang KM, Krönke J, Kuchenbauer F, Paschka P, Gaidzik VI, Döhner H, Schlenk RF, Döhner K, Bullinger L. MicroRNA expression based outcome prediction in acute myeloid leukemia - novel insights through cross-platform integrative analyses. Haematologica. 2016 Nov;101(11):e454-e456. Epub 2016 Jul 28.

91. Hezaveh K, Kloetgen A, Bernhart SH, Mahapatra KD, Lenze D, Richter J, Haake A, Bergmann AK, Brors B, Burkhardt B, Claviez A, Drexler HG, Eils R, Haas S, Hoffmann S, Karsch D, Klapper W, Kleinheinz K, Korbel J, Kretzmer H, Kreuz M, Küppers R, Lawerenz C, Leich E, Loeffler M, Mantovani-Loeffler L, López C, McHardy AC, Möller P, Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schlesner M, Scholz I, Stadler PF, Stilgenbauer S, Sungalee S, Szczepanowski M, Trümper L, Weniger MA, Siebert R, Borkhardt A, Hummel M, Hoell JI. Alterations of miRNAs and miRNA-regulated mRNA expression in GC B cell lymphomas determined by integrative sequencing analysis. Haematologica. 2016 Nov;101(11):1380-1389. Epub 2016 Jul 6.

90. Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: A study of the AML study group (AMLSG). Leukemia. 2016 Nov;30(11):2248-2250. Epub 2016 Jul 4.

89. Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodríguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Strefford JC. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia. 2016 Nov;30(11):2179-2186. Epub 2016 May 20.

88. Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016 Nov;30(11):2160-2168. Epub 2016 May 3.

87. Seymour JF, Döhner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H. Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leuk Lymphoma. 2016 Oct 14:1-12.

86. Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer. 2016 Oct 15;139(8):1759-63.

85. Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57(4):789-96.

84. Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.. Leuk Lymphoma. 2016;57(3):596-603. 

83. Walliser C, Hermkes E, Schade A, Wiese S, Deinzer J, Zapatka M, D Eacutesir Eacute L, Mertens D, Stilgenbauer S, Gierschik P. The Phospholipase C-γ2 Mutants R665W and L845F Identified in Ibrutinib-Resistant Chronic Lymphocytic Leukemia Patients are Hypersensitive to the Rho GTPase Rac2. J Biol Chem. 2016 Oct 14;291(42):22136-22148. Epub 2016 Aug 19.

82. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. Epub 2016 Sep 13.

81. Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2016 Oct;30(10):2019-2025. Epub 2016 May 2.

80. Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El-Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: Trends and outcomes over 25 years. A study by the EBMT CMWP. Leukemia. 2016 Oct;30(10):2047-2054. Epub 2016 Apr 27.

79. Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 Oct;122(19):3005-14.

78. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies). Ann Oncol. 2016 Sep;27(suppl 5):v143-v144. No abstract available.

77. Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v69-v82. 

76. Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA. Treatment recommendations for Waldenström macroglobulinemia from the Eighth International Workshop on WM. Blood. 2016 Sep 8;128(10):1321-8.

75. Papaemmanuil E, Döhner H, Campbell PJ. Genomic Classification in Acute Myeloid Leukemia. N Engl J Med. 2016 Sep 1;375(9):900-1. No abstract available.

74. Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S, Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann W, Germing U, Nolte F. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: Results from a prospective multi-center study of the German MDS study group (GMDS). Leukemia. 2016 Sep;30(9):1956-9.

73. Schmitt T, Mayer-Steinacker R, Mayer F, Grünwald V, Schütte J, Hartmann JT, Kasper B, Hüsing J, Hajda J, Ottawa G, Mechtersheimer G, Mikus G, Burhenne J, Lehmann L, Heilig CE, Ho AD, Egerer G. Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). Eur J Cancer. 2016 Sep;64:74-82.

72. Wassermann M, Woldeyes D, Gerbi BM, Ebi D, Zeyhle E, Mackenstedt U, Petros B, Tilahun G, Kern P, Romig T. A novel zoonotic genotype related to Echinococcus granulosus sensu stricto from southern Ethiopia. Int J Parasitol. 2016 Sep;46(10):663-8.

71. Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group. Bendamustine and Rituximab in Combination with Lenalidomide in Patients with Chronic Lymphocytic Leukemia. Eur J Haematol. 2016 Sep;97(3):253-60.

70. Lueck SC, Russ AC, Botzenhardt U, Schlenk RF, Zobel K, Deshayes K, Vucic D, Döhner H, Döhner K, Fulda S, Bullinger L. Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. Oncotarget. 2016 Aug 2;7(31):49539-49551. 

69. Hieke S, Benner A, Schlenk RF, Schumacher M, Bullinger L, Binder H. Integrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information. BMC Bioinformatics. 2016 Aug 30;17(1):327.

68. Meyer-Pannwitt V, Steinbrecher D, Stilgenbauer S, Mertens D. Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for chronic lympocytic leukemia? Leuk Lymphoma. 2016 Aug 22:1-2. No abstract available.

67. Scheffold A, Holtman IR, Dieni S, Brouwer N, Katz SF, Jebaraj BM, Kahle PJ, Hengerer B, Lechel A, Stilgenbauer S, Boddeke EW, Eggen BJ, Rudolph KL, Biber K. Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. Acta Neuropathol Commun. 2016 Aug 22;4(1):87.

66. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Collaborators: [...] Langer C ...Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66.

65. Louise Freeman C, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016 Aug;30(8):1763-6.

64. Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C. GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia. 2016 Aug;30(8):1734-41.

63. Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016 Aug;3(8):e388-97.

62. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75. Epub 2016 Jun 14.

61. Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016 Jul;22(7):792-9.

60. Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016 Jul;22(7):735-43.

59. Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Investigators. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma. 2016 Jul 7:1-9.

58. Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016 Jul 1;7:12050.

57. Skorka K, Zaleska J, Zajac M, Karczmarczyk A, Tomczak W, Wlasiuk P, Kowal M, Goetz M, Greiner J, Schmitt M, Giannopoulos K. Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients. Br J Haematol. 2016 Jul;174(1):155-7.

56. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42.

55. Bohl S, von Harsdorf S, Mulaw M, Hofmann S, Babiak A, Maier CP, Schnell J, Hütter-Krönke LM, Scholl K, Wais V, Schlenk RF, Bullinger L, Ringhoffer M, Döhner H, Bunjes D, Bommer M, Kuchenbauer F. Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. Bone Marrow Transplant. 2016 Jul;51(7):994-6.

54. Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia. 2016 Jul;30(7):1580-2.

53. Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Horst HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A, Döhner H, Schlenk RF. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. Haematologica. 2016 Jul;101(7):839-45.

52. Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JH, Rawat VP, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K,Döhner H, Stunnenberg HG, Feuring-Buske M, Buske C. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. Cell Rep. 2016 Jul 12;16(2):498-507.

51. Herling CD, Klaumünzer M, Krings Rocha C, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA. Complex karyotypes, KRAS and POT1 mutations impact outcome in CLL after chlorambucil based chemo- or chemoimmunotherapy. Blood. 2016 Jul 21;128(3):395-404.

50. Shostak A, Ruppert B, Ha N, Bruns P, Toprak UH; ICGC MMML-Seq Project, Eils R, Schlesner M, Diernfellner A, Brunner M. Collaborators (70) [...]Mantovani-Löffler L, Staib P, Stilgenbauer S, Ott G, Küppers R[...]. MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation. Nat Commun. 2016 Jun 24;7:11807.

49. Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016 Jun;57(6):1291-9.

48. Ernst J, Hinz A, Niederwieser D, Döhner H, Hönig K, Vogelhuber M, Mehnert A, Weissflog G. Dyadic coping of patients with hematologic malignancies and their partners and its relation to quality of life - a longitudinal study. Leuk Lymphoma. 2016 Jun 22:1-11. 

47. Keppler S, Weiβbach S, Langer C, Knop S, Pischimarov J, Kull M, Stühmer T, Steinbrunn T, Bargou R, Einsele H, Rosenwald A, Leich E. Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. Oncotarget. 2016 Jun 21;7(25):38762-38774.

46. Ernst A, Jones DT, Maass KK, Rode A, Deeg KI, Michael Chelliah Jebaraj B, Korshunov A, Hovestadt V, Tainsky MA, Pajtler KW, Bender S, Brabetz S, Gröbner S, Kool M, Devens F, Edelmann J, Zhang C, Castelo-Branco P, Tabori U, Malkin D, Rippe K, Stilgenbauer S, Pfister SM, Zapatka M, Lichter P. Telomere dysfunction and chromothripsis. Int J Cancer. 2016 Jun 15;138(12):2905-14.

45. Schmid F, Schmid M, Müssel C, Sträng JE, Buske C, Bullinger L, Kraus JM, Kestler HA. GiANT: Gene set uncertainty in enrichment analysis. Bioinformatics. 2016 Jun 15;32(12):1891-4.

44. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016 Jun 9;374(23):2209-21.

43. Savani BN, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socie' G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin NC, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A. Expanding transplant options to patients over 50 years- Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the EBMT. Haematologica.  2016 Jun;101(6):773-80.

42. Filarsky K, Garding A, Becker N, Wolf C, Zucknick M, Claus R, Weichenhan D, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D. Krüppel-Like Factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. Haematologica. 2016 Jun;101(6):e249-53.

41. Rücker FG, Lang KM, Fütterer M, Komarica V, Schmid M, Döhner H, Schlenk RF,Döhner K, Knudsen S, Bullinger L. Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. Epigenetics. 2016 Jun 16:1-9.

40. Jors K, Seibel K, Bardenheuer H, Buchheidt D, Mayer-Steinacker R, Viehrig M, Xander C, Becker G. Education in End-of-Life Care: What Do Experienced Professionals Find Important? J Cancer Educ. 2016 Jun;31(2):272-8.

39. Coburger J, Merkel A, Scherer M, Schwartz F, Gessler F, Roder C, Pala A, König R, Bullinger L, Nagel G, Jungk C, Bisdas S, Nabavi A, Ganslandt O, Seifert V, Tatagiba M, Senft C, Mehdorn M, Unterberg AW, Rössler K, Wirtz CR. Low-Grade Glioma Surgery in Intraoperative Magnetic Resonance Imaging I: Results of a Multicenter Retrospective Assessment of the German Study Group for Intraoperative Magnetic Resonance Imaging. Neurosurgery. 2016 Jun;78(6):775-86.

38. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour J, Munir T, Puvvada S, Wendtner C, Roberts A, Jurczak W, Mulligan S, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Heitner Enschede S, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda W. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016 Jun;17(6):768-78.

37. Kulkarni U, Karsten CM, Kohler T, Hammerschmidt S, Bommert K, Tiburzy B, Meng L, Thieme L, Recke A, Ludwig RJ, Pollok K, Kalies K, Bogen B, Boettcher M, Kamradt T, Hauser AE, Langer C, Huber-Lang M, Finkelman FD, Köhl J, Wong DM, Manz RA. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol. 2016 May;137(5):1487-1497.

36. Ivanova L, Buch A, Döhner K, Pohlmann A, Binz A, Prank U, Sandbaumhüter M, Bauerfeind R, Sodeik B. Conserved tryptophan motifs in the large tegument protein pUL36 are required for efficient secondary envelopment of Herpes Simplex Virus capsids. J Virol. 2016 May 12;90(11):5368-83.

35. Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H; GEKID Cancer Survival Working Group and the DRST. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. Eur J Cancer. 2016 May 10;62:1-8.

34. Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia. 2016 May;30(5):1220-5. 

33. Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. 2016 May 10;34(14):1611-9.

32. Hieke S, Benner A, Schlenk RF, Schumacher M, Bullinger L, Binder H. Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling. PLoS One. 2016 May 9;11(5):e0155226. eCollection 2016.

31. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27.

30. Heinzelmann F, Bethge W, Beelen DW, Engelhard M, Kröger N, Dreger P, Niederwieser D, Finke J, Bunjes D, Tischer J, Kobbe G, Holler E, Bornhäuser M, Stelljes M, Baurmann H, Müller A, Haubitz I, Schrezenmeier H, Müller C, Ottinger H. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. Bone Marrow Transplant. 2016 May;51(5):654-62.

29. Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C.  Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget. 2016 May 31;7(22):32532-42.

28. Theilacker C, Ludewig K, Serr A, Schimpf J, Held J, Bögelein M, Bahr V, Rusch S, Pohl A, Kogelmann K, Frieseke S, Bogdanski R, Brunkhorst FM, Kern WV; Splenectomy, Pneumococcus, and Fulminant Infection SPLEEN OFF Study Group. Collaborators: [...] Döhner H ... Overwhelming Postsplenectomy Infection: A Prospective Multicenter Cohort Study. Clin Infect Dis. 2016 Apr 1;62(7):871-8.

27. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group (Langer C). Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-34.

26. Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology. 2016 Apr 22;5(6):e1150399. eCollection 2016.

25. Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016 Apr 20;34(12):1386-94.

24. Goebeler ME, Knop S, Viardot A*, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC. (*contributed equally). Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. J Clin Oncol. 2016 Apr 1;34(10):1104-11.

23. Graeter T, Kratzer W, Oeztuerk S, Haenle MM, Mason RA, Hillenbrand A, Kull T, Barth TF, Kern P, Gruener B. Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World J Gastroenterol. 2016 Apr 7;22(13):3621-31.

22. Tausch E, Mertens D, Stilgenbauer S. Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. Oncol Res Treat. 2016;39(1-2):34-40.

21. Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, Hilgendorf I, Hirt C, Ho AD, Freund M, Schmitt M. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation. Int J Cancer. 2016 Apr 1;138(7):1792-801.

20. Kossak-Roth U, Saußele S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G, Ganser A, Giagounidis A, Gökbuget N, Griesshammer M, Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, Hehlmann R. [Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. [Article in German]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):444-53.

19. Grunenberg A, Buske C. [Waldenström's macroglobulinemia : Current developments in diagnostics and therapy]. Internist (Berl). 2016 Mar;57(3):238-44.

18. Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. Post-ibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Mar 24;127(12):1559-63.

17. Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC. Phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in relapsed/refractory diffuse large B cell lymphoma. Blood. 2016 Mar 17;127(11):1410-6.

16. Targeted Therapy Alone for Acute Promyelocytic Leukemia. Lo-Coco F, Di Donato L, Schlenk RF; for GIMEMA; German–Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia. N Engl J Med. 2016 Mar 24;374(12):1197-1198.

15. Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11;6:e404.

14. Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016 Mar;51(3):351-7.

13. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016 Mar;48(3):253-64.

12. Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562-9.

11. Bommer M, Bullinger L.  Meningeosis carcinomatosa. Der Onkologe. 2016;22(5):321-328.

10. Nowek K, Sun SM, Dijkstra MK, Bullinger L, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M. Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age. Leukemia. 2016 Feb;30(2):303-9.

9. Grunenberg A, Buske C. [New developments in Waldenström's macroglobulinemia]. Dtsch Med Wochenschr. 2016 Feb;141(3):170-2.

8. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Collaborators: ...Stilgenbauer S... Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11. Epub 2015 Dec 5.

7. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; other authors of the EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016 Feb;101(2):115-208.

6. Berendt J, Oechsle K, Thomas M, van Oorschot B, Schmitz A, Radbruch L, Simon ST, Gärtner J, Thuß-Patience P, Schuler US, Hense J, Gog C, Viehrig M, Mayer-Steinacker R, Stachura P, Stiel S, Ostgathe C. [State of integration of palliative care at Comprehensive Cancer Centers funded by German Cancer Aid]. Dtsch Med Wochenschr. 2016 Jan;141(2):e16-e23. German.

5. Schirmer M, Trentin L, Queudeville M, Seyfried F, Demir S, Tausch E, Stilgenbauer S, Eckhoff SM, Meyer LH, Debatin KM. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. Cell Death Dis. 2016 Jan 14;7:e2052.

4. Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR. STAT1 activation in association with JAK2 exon 12 mutations. Haematologica. 2016 Jan;101(1):e15-9. No abstract available.

3. Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol. 2016 Jan 10;34(2):151-9.

2. Nowek K, Sun SM, Bullinger L, Bindels EM, Exalto C, Dijkstra MK, van Lom K, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M. Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG. Leukemia.2016 Jan;30(1):229-37.

1. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15.

Publikationen 2015

 

86.  Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R, SAKK and the German CML Study Group.  Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.  Ann Hematol. 2015 Dec;94(12): 2015-24 2015-24.

85.  Stilgenbauer S.  Prognostic markers and standard management of chronic lymphocytic leukemia.  Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):368-77.

84.  Zugmaier G, Gökbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, Horst HA, Marks R, Faul C, Diedrich H, Reichle A, Brüggemann M, Holland C, Schmidt M, Einsele H, Bargou RC, Topp MS.  Long-term survival and T-Cell kinetics in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia who achieved minimal residual disease response following treatment with Anti-CD19 BiTE® antibody construct blinatumomab.  Blood. 2015 Dec 10;126(24):2578-84.    

83.  Opel D, Schnaiter A, Dodier D, Jovanovic M, Gerhardinger A, Idler I, Mertens D, Bullinger L, Stilgenbauer S, Fulda S.  Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.  Int J Cancer. 2015 Dec 15;137(12):2959-70.

82.  van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group. Urban Ch, Meister B, Fink FM, Kerbl R, Stollinger O, Schmitt K, Ebetsberger G, Jones N, Ladenstein R, Gadner H, Maes P, Brichard B, Mazzeo F, Gil T, Dhooge C, Vermorken JB, Klein A, Kruseova J, Krarup-Hansen A, Nielsen O, Capra M, Pautard B, Rialland X, Maillart P, Plouvier E, Vérité C, Bui N'guyen B, Boutard P, Delcambre C, Bay JO, Demeocq F, Couillault G, Isambert N, Plantaz D, Desfachelles AS, Piguet C, Marec-Bérard P, Blay JY, Gentet JC, Duffaud F, Bertucci F, Sirvent N, Schmitt C, Rios M, Corradini N, Rolland F, Deville A, Thyss A, Michon J, Tabone MD, Pierga JY, Millot F, Munzer M, Edan C, Vannier JP, Guillemet C, Brun E, Berger C, Castex MP, Roche H, Lejars O, Linassier C, Oberlin O, Le Cesne A, Bauer S, Ebeling P, Flasshove M, Hartmann JT, Reichardt P, Mertens R, Osieka R, Gnekow A, Schlimok G, Henze G, Thuss-Patience P, Wickmann L, Reichardt P, Potenberg J, Reichardt P, Bode U, Schmidt-Wolf IG, Eberl W, Wolff T, Pekrun A, Hofmann A, Andler W, Schneider D, Lauterbach I, Zickler P, Göbel U, Borkhardt A, Sauerbrey A, Holter W, Bauer S, Ebeling P, Flasshove M, Eggert A, Klingebiel T, Niemeyer C, Heinz J, Reiter A, Rummel M, Runde V, Lakomek M, Trümper L, Beck J, Dölken G, Lindemann HW, Körholz D, Schmoll HJ, Schneppenheim R, Hossfeld DK, Bokemeyer C, Keles H, Welte K, Klein C, Kulozik A, Egerer G, Cyran J, Strumberg D, Freier W, Graf N, Pfreundschuh M, Gruhn B, Leipold A, Bentz M, Wehinger H, Schrappe M, Nolte H, Berthold F, Wolf J, Sternschulte W, Voelpel S, Frieling T, Moessner J, Selle D, Bucsky D, Bartels H, Mohren M, Fischer T, Kluba U, Gutjahr P, Dittrich M, Reiter S, Dürken M, Neubauer A, Beyer J, Christiansen H, Erdlenbruch B, Burdach S, Schmid I, Meyer zum Büschenfelde C, Peschel C, Oduncu F, Jürgens H, Berdel W, Held H, Hofmann-Wackersreuther G, Müller H, Peters O, Andreesen R, Krause S, Heits F, Geib-König R, Kasbohm M, Bürger D, Burghard R, Dickerhoff R, Bielack S, Feddersen I, Clemens MR, Handgretinger R, Hartmann JT, Debatin KM, Mayer-Steinacker R, Schoengen A, Schlegel P, Lee V, Chik KW, van den Berg H, Rodenhuis S, Gelderblom AJ, Hoogerbrugge P, Bökkerink JP, Pieters R, Corbett R, Österlundh G, Behrendtz M, Holmqvist BM, Hjorth L, Petersen C, Jakobson Å, Hjalmars U, Ljungman G, Angst R, Kühne T, Paulussen M, Leyvraz S, Rischewski J, Feldges A, Greiner J, Hess U, Exner GU, Niggli F, Knuth A, King D, McCarthy A, Henry P, Morland B, Rees H, Nicholson J, Traunecker H, Wallace H, Ronghe M, Simpson E, Cowie F, White J, Picton S, Lewis I, Leahy M, Stark D, Selby PJ, Heney D, Pizer B, McDowell H, Michalski A, Whelan J, Chisholm J, Pritchard-Jones K, Judson I, Brennan B, Hale J, Verrill M, Walker D, Sokal M, Wheeler K, Lee V, Gerrard M, Woll P, Lorigan P, Robinson M, Kohler J. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. Eur J Cancer. 2015 Nov;51(16):2453-64.  

81. Kratzer W, Gruener B, Kaltenbach TE, Ansari-Bitzenberger S, Kern P, Fuchs M, Mason RA, Barth TF, Haenle MM, Hillenbrand A, Oeztuerk S, Graeter T. Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: Echinococcosis multilocularis Ulm classification-ultrasound. World J Gastroenterol. 2015 Nov;21(43): 12392-402.

80. Sander S, Chu VT, Yasuda T, Franklin A, Graf R, Calado DP, Li S, Imami K, Selbach M, Di Virgilio M, Bullinger L, Rajewsky K. PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones.  Immunity. 2015 Dec 15;43(6):1075-86. Epub 2015 Nov 24.

79. Hofmann S, Mead A, Malinovskis A, Hardwick NR, Guinn BA. Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunol Immunother. 2015 Nov;64(11): 1357-67.

78. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR, Morley W, Clegg S, Frost G. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015 Nov;64(11):1744-54.

77. Kurth F, Develoux M, Mechain M, Clerinx J, Antinori S, Gjørup IE, Gascon J, Mørch K, Nicastri E, Ramharter M, Bartoloni A, Visser L, Rolling T, Zanger P, Calleri G, Salas-Coronas J, Nielsen H, Just-Nübling G, Neumayr A, Hachfeld A, Schmid ML, Antonini P, Pongratz P, Kern P, Saraiva da Cunha J, Soriano-Arandes A, Schunk M, Suttorp N, Hatz C, Zoller T; TropNet Severe Malaria Investigator Group. Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study. Clin Infect Dis.  2015 Nov 1;61(9):1441-4.

76. Buske C, Kirchhoff F, Münch J. EPI-X4, a novel endogenous antagonist of CXCR4. Oncotarget. 2015 Nov 3;6(34):35137-8.

75. Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M, Eichhorst B. Outcome of advanced chronic lymphocytic leukemia following different firstline- and relapse-therapies: A metaanalysis of five prospective trials of the German CLL Study Group (GCLLSG). Haematologica. 2015 Nov;100(11):1451-9.

74. Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A, Bullinger L, Hofmann S, Götz M, Döhner K, Ihme S, Döhner H, Buske C, Feuring-Buske M, Greiner J.  Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int J Cancer. 2015 Nov 1;137(9):2083-92. 

73. Viardot A, Herfarth K, Dreyling . Indolent lymphoma. Therapy strategies. Onkologe. 2015 Oct;21(10): 936-945.

72. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22;526(7574):525-30.

71. Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, Beutner D, Rosenwald A, Stilgenbauer S, Hallek M, Benner A, Herling M. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 2015 Oct;29(10):2003-14.

70. Lennerz JK, Hoffmann K, Bubolz AM, Lessel D, Welke C, Rüther N, Viardot A, Möller P. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma. Oncotarget. 2015 Oct 6;6(30):29097-110.

69. Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F. MicroRNA-223 dose-levels fine-tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol. 2015 Oct;43(10):858-868.e7.

68. Wagener R, Aukema SM, Schlesner M, Haake A, Burkhardt B, Claviez A, Drexler HG, Hummel M, Kreuz M, Loeffler M, Rosolowski M, López C, Möller P, Richter J, Rohde M, Betts MJ, Russell RB, Bernhart SH, Hoffmann S, Rosenstiel P, Schilhabel M, Szczepanowski M, Trümper L, Klapper W, Siebert R, ICGC MMML-Seq-Project , "Molecular Mechanisms in Malignant Lymphomas" Network Project of the Deutsche Krebshilfe , Richter G, Siebert R, Wagner S, Haake A, Richter J, Eils R, Lawerenz C, Radomski S, Scholz I, Borst C, Burkhardt B, Claviez A, Dreyling M, Eberth S, Einsele H, Frickhofen N, Haas S, Hansmann ML, Karsch D, Kneba M, Lisfeld J, Mantovani-Löffler L, Rohde M, Stadler C, Staib P, Stilgenbauer S, Ott G, Trümper L, Zenz T, Hansmann ML, Kube D, Küppers R, Weniger M, Haas S, Hummel M, Klapper W, Kostezka U, Lenze D, Möller P, Rosenwald A, Szczepanowski M, Ammerpohl O, Aukema SM, Binder V, Borkhardt A, Haake A, Hezaveh K, Hoell J, Leich E, Lichter P, Lopez C, Nagel I, Pischimariov J, Radlwimmer B, Richter J, Rosenstiel P, Rosenwald A, Schilhabel M, Schreiber S, Vater I, Wagner R, Siebert R, Bernhart SH, Binder H, Brors B, Doose G, Eils J, Eils R, Hoffmann S, Hopp L, Kretzmer H, Kreuz M, Korbel J, Langenberger D, Loeffler M, Radomski S, Rosolowski M, Schlesner M, Stadler PF, Sungalee S, Barth TF, Bernd HW, Cogliatti SB, Feller AC, Hansmann ML, Hummel M, Klapper W, Lenze D, Möller P, Müller-Hermelink HK, Ott G, Rosenwald A, Stein H, Szczepanowski M, Wacker HH, Barth TF, Behrmann P, Daniel P, Dierlammm J, Haralambieva E, Harder L, Holterhus PM, Küppers R, Kube D, Lichter P, Martín-Subero JI, Möller P, Murga-Peñas EM, Ott G, Pott C, Pscherer A, Rosenwald A, Schwaenen C, Siebert R, Trautmann H, Vockerodt M, Wessendorf S, Bentink S, Berger H, Hasenclever D, Kreuz M, Loeffler M, Rosolowski M, Spang R, Stürzenhofecker B, Trümper L, Wehner M, Loeffler M, Siebert R, Stein H, Trümper L. The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma. Genes Chromosomes Cancer. 2015 Sep;54(9): 555-64.

67. Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia. 2015 Sep;29(9):1942-5. No abstract available.

66. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v100-v107. Review. No abstract available.

65. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v85-v99. Review. No abstract available.

64. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v78-v84. No abstract available.

63. Laban S, Doescher J, Schuler PJ, Bullinger L, Brunner C, Veit JA, Hoffmann TK. [Immunotherapy of head and neck tumors : Highlights of the ASCO Meeting 2015]. HNO. 2015 Sep;63(9):612-9.

62. Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL Study Group. Leuk Lymphoma. 2015 Sep 17:1-21.

61. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52.

60. Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez A, Dimitrova L, Haas S, Hoell JI, Hummel M, Karsch D, Klapper W, Kleo K, Kretzmer H, Kreuz M, Küppers R, Lawerenz C, Lenze D, Loeffler M, Mantovani-Löffler L, Möller P, Ott G, Richter J, Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schneider M, Scholz I, Stilgenbauer S, Stunnenberg HG, Szczepanowski M, Trümper L, Weniger MA; ICGC MMML-Seq Consortium, Hoffmann S, Siebert R, Iaccarino I. MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5261-70.

59. von Witzleben A, Goerttler LT, Marienfeld R, Barth H, Lechel A, Mellert K, Böhm M, Kornmann M, Mayer-Steinacker R, von Baer A, Schultheiss M, Flanagan AM, Möller P, Brüderlein S, Barth TF. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell Cycle Pathway. Cancer Res. 2015 Sep 15;75(18):3823-31.

58. Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia. 2015 Sep;29(9):1942-5. No abstract available.

57. Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood. 2015 Sep 3;126(10):1214-23.

56. Maaß C, Kletting P, Bunjes D, Mahren B, Beer AJ, Glatting G. Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody Radioimmunotherapy. Cancer Biother Radiopharm. 2015 Sep;30(7):285-290.

55. Baer C, Oakes CC, Ruppert AS, Claus R, Kim-Wanner SZ, Mertens D, Zenz T, Stilgenbauer S, Byrd JC, Plass C. Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia. Int J Cancer. 2015 Sep;137(6):1352-61.

54. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45.

53. Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015 Aug;29(8):1695-701.

52. Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: Primary results of the CLL9 trial of the German CLL Study Group. Leuk Lymphoma. 2015 Aug 21:1-22.

51. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45.

50. Wuestenberg J, Gruener B, Oeztuerk S, Mason RA, Haenle MM, Graeter T, Akinli AS, Kern P, Kratzer W. Diagnostics in cystic echinococcosis: serology versus ultrasonography. Turk J Gastroenterol. 2014 Aug;25(4):398-404.

49. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant. 2015 Aug;50(8):1057-62.

48. Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmenn P, Trněný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug;100(8):e311-4.

47. Mora-Jensen H, Jendholm J, Rapin N, Klarskov Andersen M, Roug AS, Otzen Bagger F, Bullinger L, Winther O, Borregaard N, Porse BT, Theilgaard-Mönch K. Cellular origin of prognostic chromosomal aberrations in AML patients. Leukemia. 2015 Aug;29(8):1785-9.

46. Knas T, Buck M, Stegelmann F, Möller P, Barth TF. [Detection of the BCR-ABL fusion: Comparative analysis of six commercially available FISH fusion probes]. Pathologe. 2015 Jul;36(4): 372-84.

45. Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015 Jul 9;523(7559):183-8.

44. Kortüm KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol. 2015 Jul;94(7):1205-11.

43. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9.

42. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015 Jul 16;126(3):319-27.

41. Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM, Eichhorst B, Hallek M. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015 Jul;11(13):1895-903. 

40. Richter PJ, Holtfreter M, Orhun A, Müller-Stöver I, Kubitz R, Hillenbrand A, Kratzer W, Gräter T, Grüner B. [Echinococcosis]. MMW Fortschr Med. 2015 Jun;157(12): 56-63.

39. Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung , German CML Study Group , Wernli M, Bargetzi M, Fischer von Weikersthal L, Gro V, Müller S, Hahn M, Schlimok G, Reichert D, Janssen J, Furkert J, Mandel T, Majunke PJ, Paliege R, Reichert P, Fuss H, Neben K, Staiger HJ, Heim D, Gratwohl A, Tichelli A, Korsten S, Henesser D, Le Coutre P, Arnold R, Ludwig WD, Ratei R, Teutsch C, Ludwig F, Urmersbach A, Blau I, Ihle H, Sperling C, Schelenz C, Koschuth A, Kingreen D, Heßling J, Derwahl KM, Oldenkott B, Englisch HJ, Ludwig F, Thiel E, Burmeister T, Notter M, de Wit M, Rothaug W, Büschel G, Beyer J, Dahmen E, Biaggi C, Lämmle B, Friess D, Baerlocher G, Oppliger Leibundgut E, Tobler A, Just M, Schäfer E, Behringer D, Brandt M, Schmiegel W, Vaupel HA, Verbeek W, Ko YD, Weidenhöfer S, Sauerbruch T, Hahn-Ast C, Janzen V, Schmidt-Wolf I, Trenn G, van der Linde M, Pommerien W, Fritz L, Krauter J, Lordick F, Fritsch G, Pflüger KH, Diekmann C, Kullmer J, Doering G, Munzinger H, Hertenstein B, Peyn A, Mayer J, Zácková D, Kujickova J, Stier S, Wejda B, Möller-Faßbender F, Hänel M, Morgner A, Herbst R, Matek W, Lamberti C, Zöller T, Koch B, Marth T, Henzel A, Wagner S, Woska E, Neumann F, Hoffknecht MM, Illmer T, Wolf T, Ehninger G, Kiani A, Platzbecker U, Aul C, Badrakhan CD, Giagounidis A, Flaßhove M, Henneke F, Moritz T, Simon M, Müller LL, Janz R, Eckart M, Häcker B, Rech D, Mackensen A, Krause SW, Staib P, Schlegel F, Wätzig K, Rudolph R, Wattad M, Baur FK, Heit W, Beelen DW, Hüttmann A, Novotny J, Trenschel R, Lindemann A, Linck D, Jäger E, Al-Batran SE, Ottmann OG, Serve H, Reiber T, Semsek D, Waller C, Kühnemund A, Hoeffkes HG, Lambertz H, Schulz L, Tajrobehkar K, Mittermüller J, Rummel MJ, Burchardt A, Pralle H, Runde V, Klei M, Westheider J, Hoyer A, Tessen HW, Hesse A, Trümper L, Binder C, Schmidt CA, Hirt C, Sieber M, Eschenburg H, Wilhelm S, Depenbusch R, Rösel S, Eimermacher H, Spohn C, Moeller R, Schmitz N, Nickelsen M, Engel E, Haatanen T, Hollburg W, Platz D, Köster H, Bokemeyer C, Schafhausen P, Grote-Metke A, Bechtel B, Hemeier M, Sosada M, Ganser A, Schlegelberger B, Ho AD, Rohlfing S, Dengler J, Petersen V, Porowski P, Hahn L, Dietzfelbinger H, Gröschel W, Bartholomäus A, Pfreundschuh M, Kemmerling M, Hansen R, Reeb M, Link H, Mahlmann S, Mezger J, Schatz M, Schmier M, Gatter J, Neumann S, Heymanns J, Steinmetz HT, Schmitz S, Scheid C, Planker M, Frieling T, Lollert A, Neise M, Schröder M, Greif D, Kempf B, März W, Kremers S, Müller L, Hartmann F, Heil G, Goldmann B, Heinkele P, Gregor M, Theobald M, Fischer T, Thomas S, Hensel M, Plöger C, Schuster D, Brust J, Hieber U, Hehlmann R, Neubauer A, Burchert A, Graeven U, Lange C, Schmidt G, Völkl S, Schmidt B, Hitz H, Spiekermann K, Hiddemann W, Haferlach T, Haferlach C, Schnittger S, Stötzer O, Scheidegger C, Fischer C, Berdel WE, Koppele A, Hebart H, Snaga A, Schmidt P, Hoffmann R, Reschke D, Zirpel I, Sauer M, Lenk G, Eimermacher H, Theilmann L, Sandritter B, Schenk M, Dengler R, Herr W, Krause S, Braun B, Günther E, Wacker A, Pihusch R, Baldus M, Matzdorff A, Pollmeier G, Grimminger W, Hebart H, Geer T, Schanz S, Jür C, Gassmann W, Seitz K, Kaesberger J, Mück R, Illerhaus G, Denzlinger C, Fiechtner H, Springer G, Hoffmann D, Jacki SH, Kanz L, Bross-Bach U, Döhner H, Stegelmann F, Kalhori N, Langer W, Nusch A, Wei J, Kamp T, Schadeck-Gressel C, Schwerdtfeger R, Josten KM, Klein O, Fett W, Strotkötter H, Maintz C, Groschek M, Schlag R, Elsel W, Schüler F, Dölken G, Lindemann HW, Wolf HH, Schmoll HJ, Braumann D, Hoelzer P, Kleeberg U, Hossfeld D, Lange E, Schubert J, Weischer H, Dürk HA, Kirchner HH, Bu EC, Sievers B, Freier W, Kaiser U, Peest D, Römer E, Hermann T, Fauser A, Valverde ML, Menzel J, Kemper J, Hochhaus A, La Rosée P, Bentz M, Wilhelm S, Prümmer O, Kneba M, Strack U, Schoch R, Severin K, Stauch M, Karbach U, Vehling-Kaiser U, Köchling G, Wei U, Middeke H, Neuhaus T, Martin H, Fetscher S, Schmielau J, Kämpfe D, Uppenkamp M, Wei B, Thum P, Wuillemin W, Hofmann WK, Griesshammer M, Tischler HJ, Becker M, Hanfstein B, Müller M, Saußele S, Lunscken C, Kolb HJ, Lutz L, Hentrich M, Nerl C, Wendtner C, Berdel WE, Ladda E, Gnad M, Suna H, Schmidt E, Koschmieder S, Falge C, Wandt H, Wilhelm M, Köhne CH, Schweiger C, Müller-Naendrup C, Frühauf S, Ranft K, Theilmann L, Dencausse Y, Baake G, Ritter PR, Kloke O, Becker M, Göttler B, Völkl S, Schick HD, Weidenhöfer S, Weidinger P, Wacker D, Wehmeyer J, Kreuser ED, Schlenska-Lange A, Edinger R, Andreesen R, Wehmeier A, Stahlhut K, Käfer G, Cerny T, Hess U, Priebe-Richter C, Stange-Budumlu O, Demandt M, Freunek G, Heidemann E, Schleicher J, Mergenthaler HG, Boewer C, Zeller C, Laubenstein HP, Rendenbach B, Clemens M, Waladkhani AR, Forstbauer H, Müller F, Brettner S, Raghavachar A, Kunzmann V, Goebeler ME, Gmür J. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. PLoS ONE. 2015 Jun;10(6): e0129648.

38. Kayser S, Walter RB, Stock W, Schlenk RF. Minimal Residual Disease in Acute Myeloid Leukemia-Current Status and Future Perspectives. Curr Hematol Malig Rep. 2015 Jun;10(2):132-44. 

37. Stilgenbauer S, Furman RR, Zent CS. Management of Chronic Lymphocytic Leukemia. Am Soc Clin Oncol Educ Book. 2015;35:164-175.

36. Buske C, Seymour J. Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment. Leuk Lymphoma. 2015 Jun 9:1-6. No abstract available.

35. Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T. Health-related quality of life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015 Jun;100(6):826-33.

34. Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk RF. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br J Haematol. 2015 Jun;169(5):694-700.

33. Kern P. Series: Immune Response to Parasitic Infections (Volume 2) Immunity to Helminths and Novel Therapeutic Approaches. Clin Infect Dis. 2015 Jun 1;60(11):1734.

32. Lerch K, Meyer AH, Stroux A, Hirt C, Keller U, Viardot A, Marks R, Schreiber S, Pezzutto A, Scholz CW. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Ann Hematol. 2015 Jun;94(6):981-8.

31. Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH, Fischer T. Epo-induced erythroid maturation is dependent on Plcγ1 signaling. Cell Death Differ. 2015 Jun;22(6):974-85.

30. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5): 1123-32.

29. Grishina O, Schmoor C, Döhner K, Hackanson B, Lubrich B, May AM, Cieslik C, Müller MJ, Lübbert M. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer. 2015 May 26;15(1):430.

28. Meffert C, Gaertner J, Seibel K, Jors K, Bardenheuer H, Buchheidt D, Mayer-Steinacker R, Viehrig M, Paul C, Stock S, Xander C, Becker G. Early Palliative Care-Health services research and implementation of sustainable changes: the study protocol of the EVI project. BMC Cancer. 2015 May 29;15(1):443.

27. Schneider D, Dühren-von Minden M, Alkhatib A, Setz C, van Bergen CA, Benkißer-Petersen M, Wilhelm I, Villringer S, Krysov S, Packham G, Zirlik K, Römer W, Buske C, Stevenson FK, Veelken H, Jumaa H. Lectins from opportunistic bacteria interact with acquired variable region glycans of surface Ig in follicular lymphoma. Blood. 2015 May 21;125(21):3287-96.

26. Willer A, Jakobsen JS, Ohlsson E, Rapin N, Waage J, Billing M, Bullinger L, Karlsson S, Porse BT. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia. Leukemia. 2015 May;29(5):1018-31.

25. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May;39(5):495-500.

24. Graeter T, Ehing F, Oeztuerk S, Mason RA, Haenle MM1, Kratzer W, Seufferlein T, Gruener B. Hepatobiliary complications of alveolar echinococcosis: A long-term follow-up study. World J Gastroenterol. 2015 Apr 28;21(16):4925-32.

23. Döhner K, Paschka P, Döhner H. [Acute myeloid leukemia]. Internist (Berl). 2015 Apr;56(4):354-63. German.

22. Kaltenmeier C, Gawanbacht A, Beyer T, Lindner S, Trzaska T, van der Merwe JA, Härter G, Grüner B, Fabricius D, Lotfi R, Schwarz K, Schütz C, Hönig M, Schulz A, Kern P, Bommer M, Schrezenmeier H, Kirchhoff F, Jahrsdörfer B. CD4+ T Cell-Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme B-Expressing Regulatory B Cells in HIV Patients. J Immunol. 2015 Apr 15;194(8):3768-77.

21. Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015 Apr;100(4):511-6.

20. Kayser S, Schlenk RF, Grimwade D, Yosuico VE, Walter RB. Minimal residual disease-directed therapy in acute myeloid leukemia. Blood. 2015 Apr 9;125(15):2331-2335.

19. Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann W, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2015 Apr;100(4):e122-4.

18. Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M. T cell-based targeted immunotherapies for patients with multiple myeloma. Int J Cancer. 2015 Apr 15;136(8):1751-68.

17. Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Joanna Baxter E, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015 Apr 7;6:6691.

16. Weißbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S, Leich E. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2015 Apr;169(1):57-70.

15. Tam CS, Stilgenbauer S. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? Leuk Lymphoma. 2015 Mar;56(3):587-93.

14. Paschka P, Schlenk RF, Gaidzik VI, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K. ASXL1 mutations in younger adult patients with acute myeloid leukemia: A study of the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica. 2015 Mar;100(3):324-30.

13. Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, Bunjes DW, Zhang MJ. Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9.

12. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015 Feb;5: 8535.

11. Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3 P) in -17p high risk disease. Br J Haematol. 2015 Feb;168(4):507-10.

10. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015 Feb;29(2):329-36.

9. Kaltenbach TE, Graeter T, Mason RA, Kratzer W1, Oeztuerk S, Haenle MM, Gruener B, Gottstein M. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET-CT. Nuklearmedizin. 2015 Feb 16;54(1):43-9.

8. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR. Effect of Mutation Order on Myeloproliferative Neoplasms. N Engl J Med. 2015 Feb 12;372(7):601-612.

7. Veloso Alves Pereira I, Buchmann B, Sandmann L, Sprinzl K, Schlaphoff V, Döhner K, Vondran F, Sarrazin C, Manns MP, Pinto Marques Souza de Oliveira C, Sodeik B, Ciesek S, von Hahn T. Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP). PLoS One. 2015 Feb 3;10(2):e0117152.

6. Eschbach J, von Einem B, Müller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, Weydt P, Otto M, Fauler M, Liss B, McLean PJ, Spada AR, Ludolph AC, Weishaupt JH, Danzer KM. Mutual exacerbation of peroxisome proliferator-activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization. Ann Neurol. 2015 Jan;77(1): 15-32.

5. Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, Nagler A, Blaise D, Rocha V, Cornelissen JJ, Mohty M. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia. 2015 Jan;29(1):51-7. 

4. Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, Bindels EM, Beverloo HB, Döhner H, Löwenberg B, Döhner K, Delwel R, Valk PJ. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood. 2015 Jan 1;125(1):133-9.

3. Bhattacharya N, Reichenzeller M, Caudron-Herger M, Haebe S, Brady N, Diener S, Nothing M, Döhner H, Stilgenbauer S, Rippe K, Mertens D. Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. Int J Cancer. 2015 Jan 1;136(1):65-73.

2. Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncol Res Treat. 2015;38(4):185-92.

1. Hunt L, Greenwood D, Heimpel H, Noel N, Whiteway A, King MJ. Toward the harmonization of result presentation for the eosin-5'-maleimide binding test in the diagnosis of hereditary spherocytosis. Cytometry B Clin Cytom. 2015 Jan;88(1): 50-7.

 

Publikationen 2014

 

89.  Patlewicz G, Kuseva C, Mehmed A, Popova Y, Dimitrova G, Ellis G, Hunziker R, Kern P, Low L, Ringeissen S, Roberts DW, Mekenyan O.  TIMES-SS--recent refinements resulting from an industrial skin sensitisation consortium.  SAR QSAR Environ Res. 2014;25(5):367-91. Epub 2014 May 1.  

88.  Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N.  Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group.  J Clin Oncol. 2014 Dec 20;32(36):4127-33. Epub 2014 Nov 17.  

87.  Tausch E, Stilgenbauer S.  [Chronic lymphocytic leukemia: current standards and novel approaches.]  [Article in German]  Internist (Berl). 2014 Dec;55(12):1400-9.  

86. Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Brüggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC.  Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia.  J Clin Oncol. 2014 Dec 20;32(36):4134-40. Epub 2014 Nov 10.  

85.  Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U.  GP130 activation induces myeloma and collaborates with MYC.  J Clin Invest. 2014 Dec 1;124(12):5263-74. Epub 2014 Nov 10.  

84.  Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K, Serve H, Dührsen U, Hüttmann A, Thiel E, Dengler J, Kneba M, Schaich M, Schmidt-Wolf IG, Beck J, Hertenstein B, Reichle A, Domanska-Czyz K, Fietkau R, Horst HA, Rieder H, Schwartz S, Burmeister T, Gökbuget N.  Improved outcome of adult Burkitt lymphoma/leukemia patients with rituximab and intensive chemotherapy: report of a large prospective multicenter trial.  Blood. 2014 Dec 18;124(26):3870-9. Epub 2014 Oct 30.  

83.  Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E.  Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: stem cell transplantation or novel agents?  Blood. 2014 Dec 18;124(26):3841-9. Epub 2014 Oct 9.  

82.  Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B.  Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.  Am J Hematol. 2014 Dec;89(12):E239-43. Epub 2014 Sep 26.  

81.  Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW.  Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy.  Cell Stem Cell. 2014 Dec 4;15(6):775-90.  

80.  Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K.  Differential impact of allelic ratio and insertion site in FLT3-ITD positive AML with respect to allogeneic hematopoietic stem cell transplantation.  Blood. 2014 Nov 27;124(23):3441-9. Epub 2014 Sep 30.  

79.  Weinhold N, Försti A, da Silva Filho M, Nickel J, Campo C, Hoffmann P, Nöthen MM, Hose D, Goldschmidt H, Jauch A, Langer C, Hegenbart U, Schönland SO, Hemminki K.  Immunoglobulin light chain amyloidosis shares genetic susceptibility with multiple myeloma.  Leukemia. 2014 Nov;28(11):2254-6. Epub 2014 Jul 3.  

78.  Just B, Kern P, Luthardt R, Rudolph H, Grüner B, Wahlers K.  Echinococcus cysts affecting oromaxillofacial structures--a systematic review.  Oral Dis. 2014 Nov;20(8):756-61. Epub 2014 Mar 7.  

77.  Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).  Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.  Br J Haematol. 2014 Nov;167(4):565-9. Epub 2014 Jun 30.  

76.  Risueño A, Roson-Burgo B, Dolnik A, Hernandez-Rivas JM, Bullinger L, De Las Rivas J.  A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples.  BMC Genomics. 2014 Oct 8;15(1):879.  

75.  von Baer, Ehrhardt, Baumhoer, Mayer-Steinacker, Schultheiss, Abdul-Nou, Mentzel, Fend, Möller, Jundt, Barth.  Immunohistochemical and FISH analysis of MDM2 and CDK4 in a dedifferentiated extraskeletal osteosarcoma arising in the vastus lateralis muscle: Differential diagnosis and diagnostic algorithm.  Pathol Res Pract. 2014 Oct;210(10):698-703. Epub 2014 May 22.  

74.  Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F.  Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes.  J Clin Oncol. 2014 Oct 20;32(30):3406-12. Epub 2014 Sep 22.  

73.  Jors K, Adami S, Xander C, Meffert C, Gaertner J, Bardenheuer H, Buchheidt D, Mayer-Steinacker R, Viehrig M, George W, Becker G.  Dying in cancer centers: Do the circumstances allow for a dignified death?  Cancer. 2014 Oct 15;120(20):3254-60. Epub 2014 Sep 8.  

72.  Mbaya H, Magambo J, Njenga S, Zeyhle E, Mbae C, Mulinge E, Wassermann M, Kern P, Romig T.  Echinococcus spp. in central Kenya: a different story.  Parasitol Res. 2014 Oct;113(10):3789-94. Epub 2014 Jul 24.  

71.  Rizzieri D, Vey N, Thomas X, Huguet-Rigal F, Schlenk RF, Krauter J, Kindler T, Gjertsen BT, Blau IW, Jacobsen TF, Johansen M, Bergeland T, Gianella-Borradori A, Krug U.  A phase II study of elacytarabine in combination with idarubicin and of hENT1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.  Leuk Lymphoma. 2014 Sep;55(9):2114-9. Epub 2014 Jan 24.  

70.  Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C.  Optimization of rituximab for the treatment of DLBCL (I) : Dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.  Ann Oncol. 2014 Sep;25(9):1800-6. Epub 2014 Jun 13.  

69.  Yun H, Damm F, Yap D, Schwarzer A, Chaturvedi A, Jyotsana N, Lübbert M, Bullinger L, Döhner K, Geffers R, Aparicio S, Humphries RK, Ganser A, Heuser M.  Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.  Haematologica. 2014 Sep;99(9):1456-64. Epub 2014 Jun 3.  

68.  Feurstein S, Rücker FG, Bullinger L, Hofmann W, Manukjan G, Göhring G, Lehmann U, Heuser M, Ganser A, Döhner K, Schlegelberger B, Steinemann D.  Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype.  BMC Genomics. 2014 Sep 11;15(1):784.
 

67.  Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group.  Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2014 Sep. Epub 2014 Jul 25.  

66.  Stadler CR, Vegi N, Mulaw MA, Edmaier KE, Rawat VP, Dolnik A, Bullinger L, Heilmeier B, Quintanilla-Fend L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Feuring-Buske M, Buske C.  The leukemogenicity of Hoxa9 depends on alternative splicing.  Leukemia. 2014 Sep;28(9):1838-43. Epub 2014 Feb 18.  

65.  Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, Stelljes M, Bargou RC, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N, Klinger M.  Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.  Blood Cancer J. 2014 Sep 5;4:244.  

64.  Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A; ESMO Guidelines Working Group.  Collaborators (20): Cervantes A, Pentheroudakis G, Felip E, Pavlidis N, Stahel RA, Cardoso F, Senkus-Konefka E, Arnold D, Rougier P, Horwich A, Sessa C, Colombo N, Licitra L, Buske C, Ladetto M, Peters S, Casali P, Keilholz U, Cherny N, Herrstedt J.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2014 Sep  

63.  Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M; ESMO Guidelines Working Group.
Collaborators (20): Cervantes A, Pentheroudakis G, Felip E, Pavlidis N, Stahel RA, Cardoso F, Senkus-Konefka E, Arnold D, Rougier P, Horwich A, Sessa C, Colombo N, Licitra L, Buske C, Ladetto M, Peters S, Casali P, Keilholz U, Cherny N, Herrstedt J.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2014 Sep  

62.  Kagendo D, Magambo J, Agola EL, Njenga SM, Zeyhle E, Mulinge E, Gitonga P, Mbae C, Muchiri E, Wassermann M, Kern P, Romig T.  A survey for Echinococcus spp. of carnivores in six wildlife conservation areas in Kenya.  Parasitol Int. 2014 Aug;63(4):604-11. Epub 2014 Apr 13.  

61.  Wuestenberg J, Gruener B, Oeztuerk S, Mason RA, Haenle MM, Graeter T, Akinli AS, Kern P, Kratzer W.  Diagnostics in cystic echinococcosis: serology versus ultrasonography.  Turk J Gastroenterol. 2014 Aug;25(4):398-404.  

60.  Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CD.  Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia witha sole trisomy 8.  Leukemia. 2014 Aug;28(8):1754-8. Epub Mar 21. No abstract available.  

59.  Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J.  Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy.  Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8.  

58.  Schneider V, Zhang L, Bullinger L, Rojewski M, Hofmann S, Wiesneth M, Schrezenmeier H, Götz M, Botzenhardt U, Barth TF, Döhner K, Döhner H, Greiner J.  Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.  Leukemia. 2014 Aug;28(8):1759-62. Epub 2014 Mar 28. No abstract available.  

57.  Tausch E, Mertens D, Stilgenbauer S.  Advances in treating chronic lymphocytic leukemia.  F1000Prime Rep. 2014 Aug 1;6:65. eCollection 2014.  

56.  Shivarov V, Bullinger L.  Expression profiling of leukemia patients: Key lessons and future directions.  Exp Hematol. 2014 Aug;42(8):651-60. Epub 2014 Apr 15.  

55.  Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L.  Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.  Ann Hematol. 2014 Aug;93(8):1279-86. Epub 2014 May 7.  

54.  Kühn MWM, Bullinger L, Gröschel S, Krönke J, Edelmann J, Rücker FG, Eiwen K, Paschka P, Gaidzik VG, Holzmann K, Schlenk RF, Döhner H, Döhner K.  Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations.  Haematologica. 2014 Aug;99(8):e133-5. Epub 2014 May 23.  

53.  Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R; for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group.  Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.  J Cancer Res Clin Oncol. 2014 Aug;140(8):1367-81. Epub 2014 Apr 10.  

52.  Hofmann C, Stühmer T, Schmiedl N, Wetzker R, Mottok A, Rosenwald A, Langer C, Zovko J, Chatterjee M, Einsele H, Bargou RC, Steinbrunn T.  PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.  Br J Haematol. 2014 Aug;166(4):529-39. Epub 2014 Apr 26.  

51.  Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).  MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.  Haematologica. 2014 Aug;99(8):1285-91.  

50.  Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hänel M, Witzens-Harig M, Mahlberg R, Rübe C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M.  The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.  Blood. 2014 Jul 31;124(5):720-8. Epub 2014 Jun 17.  

49.  Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).  Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.  Ann Hematol. 2014 Jul;93(7):1167-76.  

48.  Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D.  PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.  Blood. 2014 Jul 17;124(3):420-5. Epub 2014 Jun 10.  

47.  Sasca D, Hähnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV, Bullinger L, Strand S, Strand D, Theobald M, Kindler T.  SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia.  Blood. 2014 Jul 3;124(1):121-33. Epub 2014 May 22.  

46.  Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M.  Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.  Blood. 2014 Jul 3;124(1):49-62. Epub 2014 May 5.  

45.  Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S.  Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.  Blood. 2014 Jul 3;124(1):13-23. Epub 2014 Apr 24.  

44.  Hagn M, Blackwell SE, Beyer T, Ebel V, Fabricius D, Lindner S, Stilgenbauer S, Simmet T, Tam C, Neeson P, Trapani JA, Schrezenmeier H, Weiner GJ, Jahrsdörfer B.  B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.  Int Immunol. 2014 Jul;26(7):383-95. Epub 2014 Feb 4.  

43.  Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Brüderlein S, Cario H, Lubatschofski A, Welke C, Anagnostopoulos I, Barth TF, Beer AJ, Möller P, Gottstein M, Viardot A, Lennerz JK.  Potential clinical implications of BRAF mutations in histiocytic proliferations.  Oncotarget. 2014 Jun 30;5(12):4060-70.  

42.  Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF.  Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients.  Blood. 2014 Jun 26;123(26):4027-4036. Epub 2014 May 5.  

41.  Knudsen PB, Hanna B, Ohl S, Sellner L, Zenz T, Döhner H, Stilgenbauer S, Larsen TO, Lichter P, Seiffert M.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.  Leukemia. 2014 Jun;28(6):1289-98.  

40.  Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, Stilgenbauer S, Doehner H, Westermann A, Wendtner CM, Eichhorst B, Hallek M.  Interactions between comorbidity and treatment of chronic lymphocytic leukemia: trial results of the German CLL Study Group.  Haematologica. 2014 Jun;99(6):1095-1100.  

39.  Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.  Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib.  N Engl J Med. 2014 Jun 12;370(24):2286-94. Epub 2014 May 28.  

38.  Geyer HL, Emanuel RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA.  Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.  Blood. 2014 Jun 12;123(24):3803-10.  

37.  Knudsen PB, Hanna B, Ohl S, Sellner L, Zenz T, Döhner H, Stilgenbauer S, Larsen TO, Lichter P, Seiffert M.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.  Leukemia. 2014 Jun;28(6):1289-98. Epub 2013 Nov 27.

36.  Qu Y, Lennartsson A, Gaidzik VI, Deneberg S, Karimi M, Bengtzén S, Höglund M, Bullinger L, Döhner K, Lehmann S.  Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.  Epigenetics. 2014 May 27;9(8).  

35.  Thol F, Schlenk RF.  Gemtuzumab ozogamicin in acute myeloid leukemia revisited.  Expert Opin Biol Ther. 2014 May 28:1-11.  

34.  Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E  Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia.  J Clin Oncol. 2014 May 20;32(15):1586-94.  

33.  Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M.  Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network.  J Clin Oncol. 2014 May 1;32(13):1338-46.  

32.  Stilgenbauer S1, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.  Blood. 2014 May 22;123(21):3247-54.  

31.  Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G, Kröger N, Goker H, Yakoub-Agha I, Shimoni A, Mohty M, Rocha V.  Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.  Bone Marrow Transplant. 2014 May;49(5):628-33.  

30.  Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner SZ, Schirmacher P, Wulfert M, Gattermann N, Lübbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C.  Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.  Genome Med. 2014 Apr 30;6(4):34.  

29.  Gröschel S, Sanders MA, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R.  A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia.  Cell. 2014 Apr 10;157(2):369-81.  

28.  Hähnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L, Theobald M, Kindler T.  Targeting components of the alternative NHEJ pathway sensitizes KRAS-mutant leukemic cells to chemotherapy.  Blood. 2014 Apr 10;123(15):2355-66.  

27.  Weinhold N, Johnson D, Rawstron AC, Försti A, Doughty C, Vijayakrishnan J, Broderick P, Dahir N, Begum DB,  Hosking FJ, Young K,  Walker BA,  Hoffmann P,  Mühleisen TW, Langer C, Dörner E, Jöckel K-H, Eisele L, Nöthen MM, Hose D, Davies FE,  Goldschmidt H,  Morgan GJ, Hemminki K, and Houlston RS.  Inherited genetic susceptibility to monoclonal gammopathy of unknown significance  Blood. 2014 Apr 17;123(16):2513-7.  

26.  Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G.  SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.  J Clin Invest. 2014 Apr 1;124(4):1512-24.  

25.  Aukema SM1, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R.  Biologic characterization of adult MYC-translocation positive mature B-cell lymphomas other than molecular Burkitt lymphoma.  Haematologica. 2014 Apr;99(4):726-35.  

24.  Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M.  Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions.  N Engl J Med. 2014 Mar 20;370(12):1101-10.   

23.  Becker H, Yoshida K, Blagitko-Dorfs N, Claus R, Pantic M, Abdelkarim M, Niemöller C, Greil C, Hackanson B, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Döhner K, Schnittger S, Henneke P, Niemeyer CM, Flotho C, Pfeifer D, Ogawa S, Lübbert M.  Tracing the development of acute myeloid leukemia in CBL syndrome.  Blood. 2014 Mar 20;123(12):1883-6.
 

22.  Mertens D, Stilgenbauer S.  Prognostic and Predictive Factors in Patients With Chronic Lymphocytic Leukemia: Relevant in the Era of Novel Treatment Approaches?  J Clin Oncol. 2014 Mar 20;32(9):869-72.
 

21.  Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M.  Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.  Cancer. 2014 Mar 15;120(6):855-63.
 

20.  Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM.  Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.  N Engl J Med. 2014 Mar 13;370(11):997-1007.  

19.  Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA.  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.  N Engl J Med. 2014 Mar 13;370(11):1008-18.  

18.  Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR, Rassenti L, Kipps TJ, Mertens D, Lichter P, Dohner H, Stilgenbauer S, Byrd JC, Zenz T, Plass C.  Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia.  Cancer Discov. 2014 Mar;4(3):348-61.
 

17.  Pan R, Hogdal L, Benito J, Bucci D, Borthakur G, Cortes J, DeAngelo D, Debose L, Döhner H, Gaidzik V, Galinsky I, Golfman L, Han L, Haferlach T, Harutyunyan K, Hu J, Leverson J, Marcucci G, Mu H, Müschen M, Newman R, Park E, Ruvolo P, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone R, Kantarjian H, Andreeff M, Konopleva M, Letai A.  Selective BCL-2 inhibition by ABT-199 causes on target cell death in acute myeloid leukemia.  Cancer Discovery. 2014 Mar;4(3):362-75.  

16.  Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A.  Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.  Leukemia. 2014 Mar;28(3):696-8;
 

15.  Thol F, Bollin R, Gehlhaar M, Walter C, Dugas M, Suchanek KJ, Kirchner A, Huang L, Chaturvedi A, Wichmann M, Wiehlmann L, Shahswar R, Damm F, Göhring G, Schlegelberger B, Schlenk R, Döhner K, Döhner H, Krauter J, Ganser A, Heuser M.  Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.  Blood. 2014 Feb 6;123(6):914-20.
 

14.  Rapin N, Bagger FO, Jendholm J, Mora-Jensen H, Krogh A, Kohlmann A, Thiede C, Borregaard N, Bullinger L, Winther O, Theilgaard-Mönch K, Porse BT.  Comparing cancer vs. normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients.  Blood. 2014 Feb 6;123(6):894-904.
 

13.  Härter G, Frickmann H, Zenk S, Wichmann D, Ammann B, Kern P, Fleischer B, Tannich E, Poppert S.  Diagnosis of neuroschistosomiasis by antibody specificity index and semi-quantitative real-time PCR from cerebrospinal fluid and serum.  J Med Microbiol. 2014 Feb;63(Pt 2):309-12. Epub 2013 Nov 13.   

12.  Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY, Grove C, Craig J, Dittmann A, Lugo D, Jeffrey P, Drewes G, Lee K, Bullinger L, Prinjha RK, Kouzarides T, Vassiliou GS, Huntly BJ.  Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.  Leukemia. 2014 Feb;28(2):311-20   11.  Herrmann MD, Lennerz JK, Bullinger L, Bartholomae S, Holzmann K, Westhoff MA, Corbacioglu S, Debatin KM.  Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.  Exp Hematol. 2014 Feb;42(2):90-100.
 

10.  Burmeister T, Bartels G, Gröger D, Trautmann H, Schwartz S, Lenz K, Tietze-Bürger C, Viardot A, Wäsch R, Horst HA, Reinhardt R, Gökbuget N, Hoelzer D, Kneba M, Brüggemann M.  Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.  Haematologica. 2014 Feb;99(2):e23-5.  

9.  Wetzler M, Mrózek K, Kohlschmidt J, Dombret H, Döhner H, Pilorge S, Krug U, Carroll AJ, Larson RA, Marcucci G, Hiddemann W, Büchner T, Bloomfield C.  Intensive induction is effective in select octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.  Haematologica. 2014 Feb;99(2):308-13.  

8.          Griesshammer M, Döhner K.  Chronic myeloproliferative neoplasms.  Dtsch Med Wochenschr. 2014 Feb;139(6):243-6.  

7.  Kayser S and Levis MJ  FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations  Leuk Lymphoma, 2014 Feb;55(2):243-55.  

6.  Allegra D, Bilan V, Garding A, Döhner H, Stilgenbauer S, Kuchenbauer F, Mertens D.  Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia.  Leukemia. 2014 Jan;28(1):98-107.   

5.  Skórka K, Bhattacharya N, Własiuk P, Kowal M, Mertens D, Dmoszyńska A, Giannopoulos K.  Thalidomide regulation of NF-κB proteins limits Tregs activity in chronic lymphocytic leukemia.  Adv Clin Exp Med. 2014 Jan-Feb;23(1):25-32.   

4.  Edmaier KE, Stahnke K, Vegi N, Mulaw M, Ihme S, Scheffold A, Rudolph KL, Buske C.  Expression of the lymphoid enhancer factor 1 is required for normal hematopoietic stem and progenitor cell function.  Leukemia. 2014 Jan;28(1):227-30.  

3.  Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB, Tiffen JC, Kober C; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, Green AR, Massie CE, Nangalia J, Lempidaki S, Döhner H, Döhner K, Bray SJ, McDermott U, Papaemmanuil E, Campbell PJ, Adams DJ.  Inactivating CUX1 mutations promote tumorigenesis.  Nat Genet. 2014 Jan;46(1):33-8.  

2.  Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S, Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U.  Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study.  Leuk Res. 2014 Jan;38(1):57-64.  

1.  Babiak A, Steinhauser M, Götz M, Herbst C, Döhner H, Greiner J.  Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.  Oncol Rep. 2014 Jan;31(1):384-90.  

 

Publikationen 2013

 

94. Schlenk RF, Döhner H.  Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia.  Hematology Am Soc Hematol Educ Program. 2013;2013:324-30.

93.  Paschka P, Döhner K.  Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?  Hematology Am Soc Hematol Educ Program. 2013;2013:209-19.

92.  Schittenhelm MM, Illing B, Ahmut F, Rasp KH, Blumenstock G, Döhner K, Lopez CD, Kampa-Schittenhelm KM.  Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure.  PLoS One. 2013 Nov 27;8(11):e80193.

91.  Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rübe C, Zwick C, Glass B, Schmitz N, Pfreundschuh M.  Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement.  J Clin Oncol. 2013 Nov 10;31(32):4115-22.

90.  Gerull S, Stern M, Apperley J, Beelen D, Brinch L, Bunjes D, Butler A, Ganser A, Ghavamzadeh A, Koh MB, Komarnicki M, Kröger N, Maertens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socie' G, Tischer J, Oneto R, Passweg J, Marsh J.  Syngeneic transplantation in aplastic anemia: pretransplant conditioning and peripheral blood are associated with improved engraftment - an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation.  Haematologica. 2013 Nov;98(11):1804-9.

89.  Höffken G1, Kern P, Buchholz U, Ewig S, Schaberg T.  [Informations and recommendations of the German Respiratory Society and the Paul-Ehrlich-Society for chemotherapy concerning the outbreak of influenza A(H7N9) virus infections in humans]. [Article in German]  Pneumologie. 2013 Nov;67(11):599-604.

88.  Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M; ESMO Guidelines Working Group.  Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2013 Oct;24 Suppl 6:vi155-9. No abstract available.

87.  Fey MF, Buske C; ESMO Guidelines Working Group.  Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2013 Oct;24 Suppl 6:vi138-43. Epub 2013 Aug 22. No abstract available.

86.  Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F.  Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter Syndrome.  Blood. 2013 Oct 10;122(15):2673-82.

85.  Fürst D, Müller C, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B, Schrezenmeier H, Schwarz K, Mytilineos J.  High resolution HLA-matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.  Blood. 2013 Oct 31;122(18):3220-9.

84.  Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, McDonald EJ, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat J, Boultwood J.  Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.  J Clin Oncol. 2013 Oct 1;31(28):3557-64.

83.  Meilinger M, Stoeckl C, Pollheimer M, Kern P, Reisinger EC, Seeber K, Krause R, Flick H, Hoenigl M.  Progressive alveolar echinococcosis after discontinuation of anthelmintic therapy.  Parasit Vectors. 2013 Oct 1;6(1):287.

82.  Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H.  A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.  Br J Haematol. 2013 Oct;163(2):214-222.

81.  Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JAL, Neben K, Hoffmann P, Nöthen M, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H.  Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.  Nat Genet 2013 Oct;45(10):1221-5.

80.  Ringhoffer S, Rojewski M, Döhner H, Bunjes D, Ringhoffer M.  T cell reconstitution after allogeneic stem cell transplantation: assessment by the measurement of the sjTREC/βTREC-ratio and thymic naive T cells.  Haematologica. 2013 Oct;98(10):1600-1608.

79.  Wahlers K, Menezes CN, Romig T, Kern P, Grobusch MP.  Cystic echinoccosis in South Africa: the worst yet to come?  Acta Trop. 2013 Oct;128(1): 1-6.

78.  Kaasch AJ1, Rieg S, Kuetscher J, Brodt HR, Widmann T, Herrmann M, Meyer C, Welte T, Kern P, Haars U, Reuter S, Hübner I, Strauss R, Sinha B, Brunkhorst FM, Hellmich M, Fätkenheuer G, Kern WV, Seifert H; preSABATO study group.  Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study.  Infection. 2013 Oct;41(5):979-85.

77.  Iolascon A1, Heimpel H, Wahlin A, Tamary H.  Congenital dyserythropoietic anemias: molecular insights and diagnostic approach.  Blood. 2013 Sep 26;122(13):2162-6.   76.  Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud O.  CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia.  Oncotarget. 2013 Sep;4(9):1438-48.

75.  Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C.  Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change.  J Clin Oncol. 2013 Sep 10;31(26):3259-3271.

74.  Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R and  Hallek M.  Prediction of poor outcome in CLL patients following first-line 2 treatment with fludarabine, cyclophosphamide and rituximab.  Leukemia. 2013 Sep;27(9):1949-52.

73.  Mogoye BK1, Menezes CN, Wong ML, Stacey S, von Delft D, Wahlers K, Wassermann M, Romig T, Kern P, Grobusch MP, Frean J.  First insights into species and genotypes of Echinococcus in South Africa.  Vet Parasitol. 2013 Sep 23;196(3-4):427-32.

72.  Piechnik A, Dmoszynska A, Omiotek M, Mlak R, Kowal M, Stilgenbauer S, Bullinger L, Giannopoulos K.  The VEGF receptor, neuropilin-1 (NRP1) represents a promising novel target for chronic lymphocytic leukemia patients.  Int J Cancer. 2013 Sep 15;133(6):1489-96.

71.  Thoden J1, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).  Infection. 2013 Sep;41 Suppl 2:S91-115.

70.  Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG  A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies  Leuk Res. 2013 Sep;37(9):1100-6.

69.  Göbel M, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J.  Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.  PLoS One. 2013 Aug 23;8(8):e72107.   68.  Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B.  The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.  Blood. 2013 Aug 29;122(9):1576-82.

67.  Göbel M1, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J.  Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.  PLoS One. 2013 Aug 23;8(8):e72107. eCollection 2013.

66.  Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S.  NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.  Blood. 2013 Aug 15;122(7):1266-70.

65.  Greiner J, Schneider V, Schmitt M, Götz M, Döhner K, Wiesneth M, Döhner H, Hofmann S..  Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).  Blood. 2013 Aug 8;122(6):1087-8.

64.  Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA.  Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma.  N Engl J Med. 2013 Aug 8;369(6):507-16.

63.  Copley MR1, Babovic S, Benz C, Knapp DJ, Beer PA, Kent DG, Wohrer S, Treloar DQ, Day C, Rowe K, Mader H, Kuchenbauer F, Humphries RK, Eaves CJ.  The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells.  Nat Cell Biol. 2013 Aug;15(8):916-25

62.  Dickson GJ, Liberante FG, Kettyle LM, O'Hagan K, Finnegan DP, Bullinger L, Geerts D, McMullin MF, Lappin TR, Mills KI, Thompson A.  HOXA/PBX3 knockdown impairs growth and sensitizes Cytogenetically Normal AML cells to chemotherapy.  Haematologica. 2013 Aug;98(8):1216-25.

61.  Hüllein J, Jethwa A, Stolz T, Blume C, Sellner L, Sill M, Langer C, Jauch A, Paruzynski A, von Kalle C, Schmidt M, Glimm H, Zenz T.  Next-generation sequencing of cancer consensus genes in lymphoma.  Leuk Lymphoma 2013 Aug;54(8):1831-5.

60.  te Raa GD1, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).  Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.  Leuk Lymphoma. 2013 Aug;54(8):1849-53.

59.  Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner C, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stigenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K.  Second-line Therapies of Patients initially treated with Fludarabine and Cyclophosphamide (FC) or Fludarabine, Cyclophosphamide and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG).  Leuk Lymphoma. 2013 Aug;54(8):1821-2.

58.  Kugler SJ, Schnaiter A, Stilgenbauer S, Mertens D.  Missing the Notch in NOTCH1.  Leuk Lymphoma. 2013 Aug;54(8):1579-80. No abstract available.

57.  Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Dreyling M, Bohlander SK.  High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.  Leuk Lymphoma. 2013 Aug;54(8):1652-7.

56.  Haderk F, Hanna B, Richter K, Schnölzer M, Zenz T, Stilgenbauer S, Lichter P, Seiffert M.  Extracellular vesicles in chronic lymphocytic leukemia.  Leuk Lymphoma. 2013 Aug;54(8):1826-1830.

55.  Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D.  Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study.  Leuk Res. 2013 Aug;37(8):900-6.

54.  Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, Horowitz MM, Greenberg PL, Tallman MS, Dipersio JF, Bunjes D, Weisdorf DJ, Cutler C.  Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis.  J Clin Oncol. 2013 Jul 20;31(21):2662-70.

53.  Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto, the German–Austrian Acute Myeloid Leukemia Study Group, and Study Alliance Leukemia.  Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia.  N Engl J Med. 2013 Jul 11;369(2):111-121.

52.  Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwoerer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K.  Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia.  Blood. 2013 Jul 4;122(1):100-8.

51.  Schneider V, Egenrieder S, Götz M, Herbst C, Greiner J, Hofmann S.  Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.  Leuk Lymphoma. 2013 Jul;54(7):1500-4.

50.  Blijlevens N1, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D; CLWP of the EBMT. Angelucci E, Benboubker L, Blijlevens N, Browne P, Bourhis JH, Bunjes D, Carella AM, Crawley C, Christiansen I, Clausen J, Dreger P, Einsele H, Cook G, Cook M, Facon T, Fillitz M, Garderet L, Gratwohl A, Harrousseau JL, Iacopino P, Melacrino AO, Jebavy L, Kralove H, Johansson JE, Kasparu H, Ketterer N, Kienast J, Kobbe G, Krivan G, Deliliers GL, Lemoli RM, Linkesch W, Losonczy H, Maertens J, Lutz D, Meloni G, Masszi T, Morgan G, Niederwieser D, Pytlik R, Rabitsch W, Rahemtulla A, Rossi JF, Russell N, Ruutu T, Saglio G, Sonet A, Szomor A, Van Droogenbroeck PH, Zachee P.  In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.  Bone Marrow Transplant. 2013 Jul;48(7):966-71.

49.  Stolze B, Scholl C.  [Exploiting functional dependencies in cancer cells for the development of targeted therapies]  Dtsch Med Wochenschr 138:1369-1372, 2013. Article in German.

48.  Wu Y, Ihme S, Feuring-Buske M, Kuan SL, Eisele K, Lamla M, Wang Y, Buske C, Weil T.  A Core-Shell Albumin Copolymer Nanotransporter for High Capacity Loading and Two-Step Release of Doxorubicin with Enhanced Anti-Leukemia Activity.  Adv Healthc Mater. 2013 Jun;2(6):884-94.

47.  Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, Kuchenbauer F.  Circulating microRNAs in hematological diseases: principles, challenges and perspectives.  Blood. 2013 Jun 20;121(25):4977-84.

46.  Zwick C, Fadle N, Regitz E, Kemele M, Stilgenbauer S, Bühler A, Pfreundschuh M, Preuss KD.  Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells.  Blood. 2013 Jun 6;121(23):4708-17.

45.  Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, and Döhner K.  Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)  Blood. 2013 Jun 6;121(23):4769-77.

44.  Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M.  Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.  Cancer. 2013 Jun 15;119(12):2258-67.

43.  Jebaraj BM, Kienle D, Bühler A, Winkler D, Döhner H, Stilgenbauer S, Zenz T.  BRAF mutations in Chronic Lymphocytic Leukemia.  Leuk Lymphoma. 2013 Jun;54(6):1177-82.

42.  Basak GW, de Wreede LC, van Biezen A, Wiktor-Jedrzejczak W, Schmid C, Schattenberg A, Dazzi F, von dem Borne P, Petersen E, Beelen D, Abayomi A, Volin L, Buzyn A, Gurman G, Bunjes D, Olavarria E, de Witte T, Chronic Leukemia Working Party EBM  Donor lymphocyte infusions for the treatment of chronic myelogenous leukaemia relapse following peripheral blood or bone marrow stem cell transplantation.  Bone Marrow Transplant. 2013 Jun;48(6):837-42.

41.  Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken JC, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks C, Wang W, Döhner K, Jansen JH, Pahl HL.  MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.  J Exp Med. 2013 May 6;210(5):1003-19.

40.  Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J.  Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.  Mycoses. 2013 May;56(3):304-10.

39.  Binder H, Benner A, Bullinger L, Schumacher M.  Tailoring sparse multivariable regression techniques for prognostic single-nucleotide polymorphism signatures.  Stat Med. 2013 May 10;32(10):1778-91.

38.  Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.  Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.  Mol Cancer. 2013 May 24;12(1):46.

37.  Bullinger L, Schlenk RF, Goetz M, Botzenhardt U, Hofmann S, Russ AC, Babiak A, Zhang L, Schneider V, Dohner K, Schmitt M, Dohner H, Greiner J.  PRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17).  Clin Cancer Res. 2013 May 1;19(9):2562-71.

36.  Kumar M1, Witt B, Knippschild U, Koch S, Meena JK, Heinlein C, Weise JM, Krepulat F, Kuchenbauer F, Iben S, Rudolph KL, Deppert W, Günes C.  CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein-T mice during mammary carcinogenesis.  Int J Cancer. 2013 May 1;132(9):2032-43.

35.  Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S.  TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.  Blood. 2013 Apr 18;121(16):3284-8.

34.  Krivtsov AV, Figueroa ME, Sinha AU,Stubbs MC, Feng Z, Valk PJM, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.  Leukemia. 2013 Apr;27(4):852-60.

33.  Garding A, Bhattacharya N, Claus R, Ruppel M, Tschuch C, Filarsky K, Idler I, Zucknick M, Caudron-Herger M, Oakes C, Fleig V, Keklikoglou I, Allegra D, Serra L, Thakurela S, Tiwari V, Weichenhan D, Benner A, Radlwimmer B, Zentgraf H, Wiemann S, Rippe K, Plass C, Döhner H, Lichter P, Stilgenbauer S, Mertens D.  Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB.  PLoS Genet. 2013 Apr;9(4):e1003373.

32.  Schnaiter A, Stilgenbauer S.  17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.  Hematol Oncol Clin North Am. 2013 Apr;27(2):289-301.

31.  Pfeiffer T, Schleuning M, Mayer J, Haude KH, Tischer J, Buchholz S, Bunjes D, Bug G, Holler E, Meyer RG, Greinix H, Scheid C, Christopeit M, Schnittger S, Braess J, Schlimok G, Spiekermann K, Ganser A, Kolb HJ, Schmid C.  Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.  Haematologica. 2013 Apr;98(4):518-25.

30.  Richter D1, Richter J, Grüner B, Kranz K, Franz J, Kern P.  In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.  Parasitol Res. 2013 Apr;112(4):1655-60.

29.  Langer C, Rücker FG, Buske C, Döhner H, Kuchenbauer F.  Targeted therapies through microRNAs: pulp or fiction?  Ther Adv Hematol. 2012 Apr;3(2):97-104.

28.  van Vliet MH, Dumee B, Simons E, Bullinger L, Döhner K, Döhner H, Viëtor H, Löwenberg B, Valk PJ, van Beers EH.  Detection of Mutant NPM1 mRNA in Acute Myeloid Leukemia Using Custom Gene Expression Arrays.  Genet Test Mol Biomarkers. 2013 Apr;17(4):295-300.

27.  Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).  Ann Oncol. 2013 Mar;24(3):561-76.

26.  Li Z, Herold T, He C, Valk PJM, Chen P, Jurinovic V, Mansmann U, Radmacher M, Maharry K, Sun M, Yang X, Huang H, Jiang X, Sauerland M, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J.  Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study of 1,324 Patients.  J Clin Oncol. 2013 Mar 20;31(9):1172-81.

25.  Schulz A, Dürr C, Zenz T, Döhner H, Stilgenbauer S, Lichter P, Seiffert M.  Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary co-cultures by altering the myeloid microenvironment.  Blood. 2013 Mar 28;121(13):2503-11.

24.  Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, Ottersbach K, Vassiliou GS, Olivier J, Wong JW, Göttgens B, Huntly BJ, Pimanda JE.  Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.  Blood. 2013 Mar 21;121(12):2289-300.

23.  Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM.  Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.  Mol Cancer. 2013 Mar 7;12(1):19.

22.  de Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K.  Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and Treatment.  Onkologie. 2013;36(3):127-35.

21.  Kleger A, Schnell J, Essig A, Wagner M, Bommer M, Seufferlein T, Härter G.  Fecal Transplant in Refractory Clostridium difficile Colitis.  Dtsch Arztebl Int. 2013 Feb;110(7):108-15.

20.  Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong G, Kunjamma RB, Ren H, He C, Wang C, Elkahloun A, Valk P, Doehner K, Neilly MB, Bullinger L, Delwel R, Lowenberg B, Liu PP, Morgan R, Rowley JD, Yuan C, Chen J.  PBX3 is an important cofactor of HOXA9 in leukemogenesis.  Blood. 2013 Feb 21;121(8):1422-31.

19.  Jebaraj BM, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, Rosenwald A, Barth TF, Möller P, Zenz T, Döhner H, Stilgenbauer S.  Telomere length in mantle cell lymphoma.  Blood. 2013 Feb 14;121(7):1184-7.   18.  Garding A, Bhattacharya N, Haebe S, Mueller F, Weichenhan D, Idler I, Ickstadt K, Stilgenbauer S, Mertens D.  TCL1A and ATM are coexpressed in chronic lymphocytic leukemia cells without deletion of 11q.  Haematologica. 2013 Feb;98(2):269-73.

17.  Bommert KS, Effenberger M, Leich E, Küspert M, Murphy D, Langer C, Janz S, Moll R, Motto A, Rosenwald A, Bargou R, Bommert K.  The feed-forward loop between YB-1 and MYC is essential for Multiple Myeloma cell survival.  Leukemia. 2013 Feb;27(2):441-50.

16.  Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L.  Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.  Leukemia. 2013 Feb;27(2):353-61.

15.  Leich E, Weißbach S, Klein H-U, Grieb T, Pischimarov J, Stühmer S, Chatterjee M, Steinbrunn T, Langer C, Eilers M, Einsele, H, *Bargou R, and *Rosenwald A:  Multiple Myeloma is Affected by Multiple and Heterogeneous Somatic Mutations in Adhesion- and Receptor Tyrosine Kinase Signaling Molecules.  Blood Cancer J. 2013 Feb 8;3:e102. (*equal contribution).

14.  Schlenk RF, Döhner K, Döhner H.  [Acute myeloid leukemia : Genetic diagnostics and molecular therapy.]  Internist (Berl). 2013 Feb;54(2):171-8. German.   13.  Salaverria I1, Martin-Guerrero I, Burkhardt B, Kreuz M, Zenz T, Oschlies I, Arnold N, Baudis M, Bens S, García-Orad A, Lisfeld J, Schwaenen C, Szczepanowski M, Wessendorf S, Pfreundschuh M, Trümper L, Klapper W, Siebert R.  High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.  Genes Chromosomes Cancer. 2013 Feb;52(2):150-5.

12.  Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K.  Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).  Blood. 2013 Jan 3;121(1):170-7.

11.  Fernández-Sáiz V, Targosz B, Lemeer S, Eichner R, Langer C, Bullinger L, Reiter C, Slotta-Huspenina J, Schroeder S, Knorn A, Kurutz J, Peschel C, Pagano M, Kuster B, Bassermann F.  SCFFbxo9 and CK2direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma.  Nat Cell Biol. 2013 Jan;15(1):72-81.

10.  Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Farhadi Sartangi N, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD.  FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and iImply the clinical use of tyrosine kinase inhibitors.  PLoS One. 2013;8(1):e53190.

9.  Wei QX, Claus R, Hielscher T, Mertens D, Raval A, Oakes CC, Tanner SM, de la Chapelle A, Byrd JC, Stilgenbauer S, Plass C.  Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia.  PLoS One. 2013;8(1):e55261.

8.  Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Döhner K, Vasioukhin V, Fischer T, Armstrong SA.  The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.  J Exp Med. 2013 Jan 14;210(1):15-22.

7.  Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S.  CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR? signaling.  J Clin Invest. 2013 Jan 2;123(1):299-314.

6.  Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A.  90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.  J Clin Oncol. 2013 Jan 20;31(3):308-13.

5.  Hofmann S, Götz M, Schneider V, Guiallaume P, Bunjes D, Döhner H, Wiesneth M, Greiner J.  Donor lymphocyte infusion polyspecific CD8+ T cell responses with concurrent molecular remission in AML with NPM1 mutation.  J Clin Oncol. 2013 Jan 20;31(3):e44-7.

4.  Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn WM, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IGH, Berna Beverloo H, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Krauter J, Ganser A, Valk PJM, Löwenberg B, Döhner K, Döhner H*, Delwel R*  Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups.  J Clin Oncol. 2013 Jan 1;31(1):95-103. (* equal contribution)   3.  Sun SM, Rockova V, Bullinger L, Dijkstra MK, Döhner H, Löwenberg B, Jongen-Lavrencic M.  The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.  Leukemia. 2013 Jan;27(1):100-6.

2.  Lin K, Lane B, Carter A, Johnson GG, Onwuazor O, Oates M, Zenz T, Stilgenbauer S, Atherton M, Douglas A, Ebrahimi B, Sherrington PD, Pettitt AR.  The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.  Br J Haematol. 2013 Jan;160(1):53-62.

1.  Herzberg PY1, Lee SJ, Heussner P, Mumm FH, Hilgendorf I, von Harsdorf S, Hemmati P, Rieger K, Greinix HT, Freund M, Holler E, Wolff D.  Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center.  Bone Marrow Transplant. 2013 Jan;48(1):129-34.  © 2017 Universitätsklinikum Ulm

 

Publikationen 2012

 

106.  Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Möller P, MacLeod RA, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler PF, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R; ICGC MMML-Seq Project  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.  Nat Genet. 2012 Dec;44(12):1316-20.  

105.  Addy F, Alakonya A, Wamae N, Magambo J, Mbae C, Mulinge E, Zeyhle E, Wassermann M, Kern P, Romig T  Prevalence and diversity of cystic echinococcosis in livestock in Maasailand, Kenya.  Obstet Gynecol. 2012 Dec;111(6):2289-94.  

104.  Barth TF, Herrmann TS, Tappe D, Stark L, Grüner B, Buttenschoen K, Hillenbrand A, Juchems M, Henne-Bruns D, Kern P, Seitz HM, Möller P, Rausch RL, Kern P, Deplazes P  Sensitive and specific immunohistochemical diagnosis of human alveolar echinococcosis with the monoclonal antibody Em2G11.  PLoS Negl Trop Dis. 2012;6(10): e1877  

103.  Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K, Piechnik A, Bojarska-Junak A, Dmoszynska A, Giannopoulos K  Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.  PLoS ONE. 2012;7(4): e35178
 102.  Keller F, Wiesner S, Bunjes D, Hartmann B, Schmitt M.  Safety and efficacy of everolimus after kidney and hematopoietic stem cell transplantation.  Ann Transplant. 2012 Dec 31;17(4):52-8.  

101.  Topp MS, Gökbuget N, Zugmaier G, Degenhardt E, Goebeler ME, Klinger M, Neumann Md SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Köhne-Volland R, Brueggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou RC.  Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL).  Blood. 2012 Dec 20;120(26):5185-7.  

100.  Kühn MW, Blagieva R, Beha D, Hänle M, Reister F, Henne-Bruns D, Pilcher C, Böhm BO, von Wichert G.  [A 31-year-old pregnant woman with refractory hypercalcemia.]  Internist (Berl). 2012 Dec;53(12):1490-5 .  

99.  Bamezai S, Rawat VP, Buske C.  The Piwi - piRNA Axis: Pivotal Beyond Transposon Silencing.  Stem Cells. 2012 Dec;30(12):2603-11.  

98.  Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M.  Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCam) in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.  Leukemia. 2012 Dec;26(12):2549-52.  

97.  Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B.  Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma.  J Clin Oncol. 2012 Dec 20;30(36):4462-9.  

96.  Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; for the German High-Grade Lymphoma Study Group (DSHNHL).  Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).  Lancet Oncol. 2012 Dec;13(12):1250-1259.  

95.  Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A,  Bloehdorn J, Radtke I,  Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S and Döhner H.  High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations.  Blood. 2012 Dec 6;120(24):4783-94.  

94.  Zhang L, Götz M, Hofmann S, Greiner J  Immunogenic targets for specific immunotherapy in multiple myeloma.
Clin Dev Immunol. 2012;2012: 820394  

93  Lechner CJ, Grüner B, Huang X, Hoffmann WH, Kern P, Soboslay PT  Parasite-specific IL-17-type cytokine responses and soluble IL-17 receptor levels in Alveolar Echinococcosis patients.  Clin Dev Immunol. 2012;2012: 735342  

92.  Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA  Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.  J Clin Oncol. 2012 Nov 20;30(33): 4098-103  

91.  Wahlers K, Menezes CN, Wong ML, Zeyhle E, Ahmed ME, Ocaido M, Stijnis C, Romig T, Kern P, Grobusch MP  Cystic echinococcosis in sub-Saharan Africa.  Lancet Infect Dis. 2012 Nov;12(11):871-80.  

90.  Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M.  Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012 Nov;91(11):1765-72. Review.   89.  Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Dürig J, Küppers R.  Cellular origin and pathophysiology of chronic lymphocytic leukemia.  J Exp Med. 2012 Nov 19;209(12):2183-98.  

88.  Bethge WA, von Harsdorf S, Bornhauser M, Federmann B, Stelljes M, Trenschel R, Baurmann H, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D.  Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.  Bone Marrow Transplant. 2012 Nov;47(11):1397-402.  

87.  Grasedieck S, Schöler N, Bommer M, Niess JH, Tumani H, Rouhi A, Bloehdorn J, Liebisch P, Mertens D, Döhner H, Buske C, Langer C*, Kuchenbauer F.  Impact of serum storage conditions on microRNA stability.  Leukemia. 2012 Nov;26(11):2414-6. *equal contribution  

86.  Ringdén O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, Greinix HT, Kyrcz-Krzemien S, Bunjes D, Brinch L, Niederwieser D, Arnold R, Mohty M, Rocha V; for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).  Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukemia, an Acute Leukemia Working Party analysis in 2262 patients.  J Intern Med. 2012 Nov;272(5):472-483.  

85.  Gruber TA, Gedman AL, Zhang J, Koss CS, Marada S, Ta HQ, Chen S-C, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R,  Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SP,  Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang D-C, Rubnitz JE, Pui C-H, Mardis ER, Wilson RK, and Downing JR.  An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia.  Cancer Cell. 2012 Nov 13; 22: 683–697.  

84.  Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MWM, Paschka  P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L.
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin-remodeling and splicing.  Blood. 2012 Nov 1;120(18):e83-92.  

83.  Struve S, Wendtner CM  [Prevention and treatment of venous thromboembolism in patients with cancer].  Dtsch Med Wochenschr. 2012;137(40): 2007-9  

82.  Fröhling S  Widespread over-expression of the non-clustered homeobox gene HLX in acute myeloid leukemia.  Haematologica. 2012;97(10): 1453  

81.  Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.  Nature. 2012 Oct 4;490(7418):116-20.  

80. Bruns H, Stegelmann F, Fabri M, Döhner K, van Zandbergen G, Wagner M, Skinner M, Modlin RL, Stenger S.  Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages.  J Immunol. 2012 Oct 15;189(8):4069-78.  

79.  Döhner K, Stegelmann F, Schlenk RF, Griesshammer M.  [Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms].  Dtsch Med Wochenschr. 2012 Oct;137(42):2171-8. German.  

78.  Nagel G, Stocks T, Späth D, Hjartåker A, Lindkvist B, Hallmans G, Jonsson H, Bjørge T, Manjer J, Häggström C, Engeland A, Ulmer H, Selmer R, Concin H, Stattin P, Schlenk RF.  Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can).  Ann Hematol. 2012 Oct;91(10):1519-31.  

77.  Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Späth D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann V, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M.  Acute Myeloid Leukemia: Different Treatment Strategies versus a Common Standard Arm – a Combined Prospective Analysis by the German AML Intergroup  J Clin Oncol. 2012 Oct 10;30(29):3604-10.  

76.  Scholtysik R, Nagel I, Kreuz M, Vater I, Giefing M, Schwaenen C, Wessendorf S, Trümper L, Loeffler M, Siebert R, Küppers R  Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.  Int J Cancer.2012 Sep 1;131(5): E830-5  

75.  Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Råcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.  Nat Rev Clin Oncol. 2012 Sep 4;9(10):579-90.  

74.  Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, McMullin MF, Boiron JM, Döhner K, Vannucchi AM, Besses C, Campbell PJ, Green AR.
JAK2V617F-homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
Blood. 2012 Sep 27;120(13):2704-7.  

73.  Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM.  Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group.  J Clin Oncol. 2012 Sep 10;30(26):3209-16.  

72.  Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C, Kobbe G, Finke J, Germing U, Mohr B, Greiner J, Beelen D, Thiede C, Ehninger G, Platzbecker U; on behalf of the German MDS and Cooperative Transplant Study Group (GCTSG).  Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.  Haematologica. 2012 Sep;97(9):e34-e35. No abstract available.  

71.  Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Büchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C.  High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.  Blood. 2012 Sep 6;120(10):2118-26.  

70.  Gökbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Hüttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors and realization of stem cell transplantation.  Blood. 2012 Sep 6;120(10):2032-2041.  

69.  Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A; for the SAKK and the German CML Study Group.  Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).  Leukemia. 2012 Sep;26(9):2096-102.  

68.  Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrcz-Krzemien S, Rocha V, Mohty M.  Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: an Analysis from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation.  Biol Blood Marrow Transplant. 2012 Sep;18(9):1422-9.  

67.  Kächele V, Schneider-Kappus W, Bommer M  [Pronounced pancytopenia with concomitant jaundice in a 66-year-old woman].  Dtsch Med Wochenschr. 2012;137(34-35): 1693-6  

66.  Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT  Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.
Cancer Cell. 2012 Aug 14;22(2):209-21  

65.  Mar BG*, Bullinger L*, Basu E, Schlis K, Silverman LB, Döhner K, Armstrong SA.  Sequencing histone modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia.  Leukemia. 2012 Aug;26(8):1881-3.  (*authors contributed equally).  

64.  Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH.  Treatment of older patients with mantle-cell lymphoma.  N Engl J Med. 2012 Aug 9;367(6):520-31.  

63.  Greiner J, Ono Y, Hofmann  S, Schmitt A, Mehring E, Götz M, Guillaume P, Döhner K, Mytilineos J, Döhner H, Schmitt M.  Mutated regions of nucleophosmin 1 (NPM1) elicit both CD4+ and CD8+ T cell responses in patients with acute myeloid leukemia (AML).  Blood. 2012 Aug 9;120(6):1282-9.  

62.  Sander S, Calado DP, Srinivasan L, Köchert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K.  Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis.  Cancer Cell. 2012 Aug 14;22(2):167-79.  

61.  Gusscott S, Kuchenbauer F, Humphries RK, Weng AP  Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL.  Leuk Res. 2012 Jul;36(7):905-11.  

60.  Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T, European Research Initiative on CLL (ERIC)  ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.  Leukemia. 2012 Jul;26(7):1458-61.  

59.  Faderl S, Wetzler M, Rizzieri DA, Schiller GJ, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang E, Vasconcelles M, Huebner D, Kantarjian HM.  Clofarabine Plus Cytarabine Compared with Cytarabine Alone in Older Patients with Relapsed or Refractory Acute Myelogenous Leukemia: Results from the Randomized, Double-Blind, Placebo-Controlled Phase 3 CLASSIC I Trial.  J Clin Oncol. 2012 Jul 10;30(20):2492-9.  

58.  Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; for the NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.  Lancet Oncol. 2012 Jul;13(7):707-15.  

57.  Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC.  Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia.  J Clin Oncol. 2012 Jul 10;30(20):2483-91.  

56.  Rawat VP, Humphries RK, Buske C.  Beyond HOX: the role of ParaHox genes in normal and malignant hematopoiesis.  Blood. 2012 Jul 19;120(3):519-27.  

55.  Claus R, Hackanson B, Poetsch AR, Zucknick M, Sonnet M, Blagitko-Dorfs N, Hiller J, Wilop S, Brümmendorf TH, Galm O, Platzbecker U, Byrd JC, Döhner K, Döhner H, Lübbert M, Plass C.  Quantitative analyses of DAPK1 methylation in AML and MDS.  Int J Cancer. 2012 Jul 15;131(2):E138-42.  

54.  Lammel V, Stoeckle C, Padberg B, Zweifel R, Kienle DL, Reinhart WH, Simon HU  Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung.
Lung Cancer. 2012 Jun;76(3):493-5.   53.  Bouchaud O, Mühlberger N, Parola P, Calleri G, Matteelli A, Peyerl-Hoffmann G, Méchaï F, Gautret P, Clerinx J, Kremsner PG, Jelinek T, Kaiser A, Beltrame A, Schmid ML, Kern P, Probst M, Bartoloni A, Weinke T, Grobusch MP  Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study.  Malar J. 2012 Jun 22;11:212.  

52.  Yang Y, Shaffer AL, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Cancer Cell. 2012 Jun 12;21(6): 723-37  

51.  Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P.  Immunopharmacological response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.  Blood. 2012 Jun 28;119(26):6226-33.  

50.
Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR.  EVI1 is critical for the pathogenesis of a subset of MLL-AF9 rearranged AMLs.  Blood. 2012 Jun 14;119(24):5838-49.  

49.  Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P.  Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.  J Clin Oncol. 2012 Jun 20;30(18):2211-7.  

48.  Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J and Giagounidis A.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.  Leukemia. 2012 Jun;26(6):1286-92.  

47.  Oehrlein K, Langer C, Sturm I, Pönisch W, Hahn-Ast C, Kuhn S, Weisel KC.  Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 german centers.  Clin Lymphoma Myeloma. Leuk. 2012 Jun;12(3):191-6.  

46.  Liu J, Mercher T, Scholl C, Brumme K, Gilliland DG, Zhu N.  A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells.  Exp Hematol. 2012 Jun;40(6):487-498.e3.  

45.  Mulaw MA, Krause A, Krause AJ, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK  CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12.
Leukemia. 2012 May;26(5):1012-9.  

44.  Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S  RBC-transfusion guidelines update.
Leuk Res. 2012 May;36(5):659-60.  

43.  Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, and Stilgenbauer S.  Early autologous stem cell transplantation for chronic lymphocytic leukemia: Long-term follow-up of the GCLLSG CLL3 trial.  Blood. 2012 May 24;119(21):4851-4859.  

42.  Nückel H, Langer C, Herget-Rosenthal S, Wichert M, Assert R, Döhner H, Dührsen U, Liebisch P.  Prognostic significance of serum cystatin C in multiple myeloma.  Int J Hematol. 2012 May;95(5):545-50.  

41.  Möller P, Viardot A.  Antibiotics as first-line therapy for Hp-associated gastric large B-cell lymphoma? Probably yes.  Blood. 2012 May 24;119(21):4818-9. No abstract available.  

40.  Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bokisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, and the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.  Lancet. 2012 May 12;379(9828):1791-9. Erratum in: Lancet. 2012 May 12;379(9828):1790.  

39.  Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K.  The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.  Blood. 2012 May 10;119(19):4383-6.  

38.  Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma.  N Engl J Med. 2012 May 10;366(19):1759-69.  

37.  Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S.  Risk categories and refractory CLL in the era of chemoimmunotherapy.  Blood. 2012 May 3;119(18):4101-7.  

36.  Noordermeer SM, Monteferrario D, Sanders MA, Bullinger L, Jansen JH, van der Reijden BA.  Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression.  Blood. 2012 May 3;119(18):4335-7.  

35.  Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, Windfeld K, Viardot A; for the 409 Study Investigators.  Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma.  Br J Haematol. 2012 May;157(4):438-445.  

34.  Pauls S, Fischer AC, Brambs HJ, Fetscher S, Höche W, Bommer M.  Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors.  Eur J Radiol. 2012 May;81(5):974-8.  

33.  Gasparetto M, Sekulovic S, Brocker C, Tang P, Zakaryan A, Xiang P, Kuchenbauer F, Wen M, Kasaian K, Witty MF, Rosten P, Chen Y, Imren S, Duester G, Thompson DC, Humphries RK, Vasiliou V, Smith C  Aldehyde dehydrogenases are regulators of hematopoietic stem cell numbers and B-cell development.
Exp Hematol. 2012 Apr;40(4):318-29.e2.  

32.  Härter G, Michel D  Antiviral treatment of cytomegalovirus infection: an update.  Expert Opin Pharmacother. 2012 Apr;13(5):623-7.  

31.  Viardot A  [Malignant lymphomas: clinical appearance, classification, therapy and prognosis].  Radiologe. 2012 Apr;52(4):321-9.  

30.  Kovaleva V, Mora R, Park YJ, Plass C, Chiramel A, Bartenschlager R, Döhner H, Stilgenbauer S, Pscherer A, Lichter P, Seiffert M.  miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells.  Cancer Res. 2012 Apr 1;72(7):1763-72.  

29.  Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD, Tanner SM and de la Chapelle A.  Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.  Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6668-73.  

28.  de Wit TD, Borkhardt A, Chomienne C, Döhner H, Fibbe WE, Foà R, Hagenbeek A, Skoda RC, Smand CR, Jäger U.  Raising hematology's European voice: the importance of calling yourself a hematologist.  Haematologica. 2012 Apr;97(4):476-8.  

27.  Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne C, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K.  TET2 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis of the AML Study Group (AMLSG).  J Clin Oncol. 2012 Apr 20;30(12):1350-7.  

26.  Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S,* Scholl C.*  Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.  J Exp Med. 2012 Apr 9;209(4):697-711. *Equal contribution.  

25.  Azimzadeh O, Scherthan H, Yentrapalli R, Barjaktarovic Z, Ueffing M, Conrad M, Neff F, Calzada-Wack J, Aubele M, Buske C, Atkinson MJ, Hauck SM, Tapio S.  Label-free protein profiling of formalin-fixed paraffin-embedded (FFPE) heart tissue reveals immediate mitochondrial impairment after ionising radiation.  J Proteomics. 2012 Apr 18;75(8):2384-95.  

24.  Heidel FH, Bullinger L, Neff TA, Feng Z, Wang Z, Stein L, Kalaitzidis D, Lane SW, Armstrong SA.  Genetic and Pharmacologic Inhibition of ß-Catenin Targets Imatinib Resistant Leukemia Stem Cells in CML.  Cell Stem Cell. 2012 Apr 6;10(4):412-24.  

23.  Xu C, Plattel W, van den Berg A, Rüther N, Huang X, Wang M, de Jong D, Vos H, Van Imhoff G, Viardot A, Möller P, Poppema S, Diepstra A, Visser L.  Expression of the c-Met oncogene by tumor cells predicts favorable outcome in classical Hodgkin lymphoma.  Haematologica. 2012 Apr;97(4):572-8.  

22.  Mertens D, Stilgenbauer S.  CLL and deletion 13q14: merely the miRs?  Blood. 2012 Mar 29;119(13):2974-5. No abstract available.  

21.  Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M.  Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial.  J Clin Oncol. 2012 Mar 20;30(9):980-8.  

20.  Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Döhner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, Chen J.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically-abnormal AML.  Blood. 2012 Mar 8;119(10):2314-24.  

19.  Kühn MW*, Radtke I*, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H*, Downing JR*.  Resolution Genomic Profiling of Adult and Pediatric Core-Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Alterations.  Blood. 2012 Mar 8;119(10):e67-75.   *equal contribution   18.  Bauduer M, Gribben J, Herrmann R, Thiel E, Rai K, Larson R, Ferrara F, Barnard J, Pearce H, Taylor C, Brillant C, Steurer M, Weingart O, Flinn IW, Funkhouser A, Tallman M, Sun Z, Jaksic B, Suciu S, Chevret S, Dighiero G, Leporrier M, Frankel SR, Sirard C, Hillmen P, Trehu B, Felder M, Busch R, Eichhorst B, Hallek M, Stilgenbauer S, Pangalis G, Bezares R, van Oers MHJ, van Putten W, Gobbi M, Spriano M, Mabed M, Catovsky D, Richards S, Wade R, Abdelhamid T, Dearden C, Knauf W, Blonski J, Jamroziak K, Robak T, Mauro F, Hiddeman W, Johnson SA, Longthorne G, Rummel MJ, Juliusson G, Pulluqi P, Zinzani PL, Pozzato G, Reynolds C, Furman RR, Durrant J, Elphinstone P, Evans V, Gettins L, Hicks C, James S, Clarke M, MacKinnon L, McHugh TM, Morris P, Read S, Gregory C, CLL Trialists Collaborative Grp  Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials.  Haematologica. 2012 Mar;97(3):428-36.  

17.  Lübbert M, Rüter B, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans P, Döhner H.
A multicenter phase II trial of Decitabine as first-line treatment of older AML patients judged unfit for induction chemotherapy.
Haematologica. 2012 Mar;97(3):393-401.  

16.  Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.  Blood. 2012 Mar 1;119(9):2114-21.  

15.  Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA.  Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.  Leuk Lymphoma. 2012 Mar;53(3):417-23.  

14.  Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, Zoi K, Ernst T, Stegelmann F, Döhner K, Chase A, Cross NC.
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.  Blood. 2012 Feb 2;119(5):1208-13.  

13.  Damm F, Bunke T, Thol F, Markus B, Wagner K, Göhring G, Schlegelberger B, Heil G, Reuter CW, Püllmann K, Schlenk RF, Döhner K, Heuser M, Krauter J, Döhner H, Ganser A, Morgan MA.  Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.  Leukemia. 2012 Feb;26(2):289-95.  

12  Bullinger L, Fröhling S.  Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights.  Semin Oncol. 2012 Feb;39(1):37-46.  

11.  Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, Scholl C, Fröhling S, Carr SA, Stern AM, Schreiber SL, Golub TR.
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.
Proc Natl Acad Sci USA. 2012 Feb 21;109(8):2860-5.  

10.  Schroeder T, Kuendgen A, Kayser S, Kroeger N, Braulke F, Platzbecker U, Klarner V, Zohren F, Haase D, Stadler M, Schlenk RF, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U.  Therapy-related myeloid neoplasms following treatmentwith radioiodine.  Haematologica. 2012 Feb;97(2):206-12.  

9.  Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ.  Classifying Cytogenetics in Patients with AML in Complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study.  Biol Blood Marrow Transplant. 2012 Feb;18(2):280-8.  

8.  Kayser S, Schlenk RF.  Genetic and immunophenotypical diagnostics for acute myeloid  leukemia and their implication on treatment strategy  J Lab Med. 2012;36(1):37–45.  

7.  Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, Hummel M, Loeffler M, Pellissery S, Woessmann W, Schwänen C, Trümper L, Wessendorf S, Spang R, Hasenclever D, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe  Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.  Blood. 2012 Feb 23;119(8):1882-7.  

6.  Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zettl U UK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F  Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
J Neuroinflammation.  2012 Jan 19;9: 14  

5.  Herold T, Seiler T, Egensperger R, Trumm C, Bergmann M, Franke D, Mumm FF, Schinwald N, Buske C, Dreyling M.  Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.  Leuk Lymphoma. 2012 Jan;53(1):169-72. No abstract available.  

4.  Arnold F, Schnell J, Zirafi O, Stürzel C, Meier C, Weil T, Ständker L, Forssmann WG, Roan NR, Greene WC, Kirchhoff F, Münch J.  Naturally Occurring Fragments from Two Distinct Regions of the Prostatic Acid Phosphatase Form Amyloidogenic Enhancers of HIV Infection.  J Virol. 2012 Jan;86(2):1244-9.  

3.  Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO.  Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations.  Cell. 2012 Jan 20;148(1-2):59-71.  

2.  Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K.  Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).  Ann Hematol. 2012 Jan;91(1):9-18.  

1.  Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H and Schlenk RF, for the German-Austrian AMLSG:  Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.  Blood. 2012 Jan 12;119(2):551-558.